Paths to Tier 1 Genomics Implementation: A Survey of Chronic Disease Directors by Ponte, Amy
Walden University
ScholarWorks
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral StudiesCollection
2017
Paths to Tier 1 Genomics Implementation: A
Survey of Chronic Disease Directors
Amy Ponte
Walden University
Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Genetics Commons, and the Public Health Education and Promotion Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been













This is to certify that the doctoral dissertation by 
 
 
Amy H. Ponte 
 
 
has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  




Dr. Ji Shen, Committee Chairperson, Health Services Faculty 
Dr. Nicoletta Alexander, Committee Member, Health Services Faculty 






Chief Academic Officer 















Paths to Tier 1 Genomics Implementation: A Survey of Chronic Disease Directors 
by 
Amy H. Ponte 
 
MPH, University of Connecticut, 2000 
BS, Quinnipiac University, 1985 
 
 
Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 









Although evidence is currently available for population-based genetic screening and 
testing of individuals and their family members for certain hereditary chronic disease 
conditions (Tier 1), few states have integrated these genomic applications into chronic 
disease prevention programs. State and territorial chronic disease directors (CDDs) could 
provide the leadership needed to deliver these applications in more states. The purpose of 
this study was to determine whether an association exists between current chronic disease 
genomics funding or specific state genomic activities and the level of knowledge and 
interests in genomics by these directors. Rogers’s diffusion of innovations (DIT) theory 
was used to explain the current climate of state chronic disease genomics and the need for 
an innovation champion to promote these evidence-based applications both in and out of 
the state health departments. A nonexperimental, cross-sectional, correlational survey of 
CDDs (N = 58) was performed using the Chronic Disease Director’s Survey and results 
were analyzed using chi-square, independent t test, ANOVA, logistic regression, and 
Pearson’s correlation coefficient. Results showed CDDs knowledge of genomics is 
unrelated to current state funding; however, CDD knowledge and interest in genomics 
was associated with inclusion of genetics in cancer control and cardiovascular health 
action plans, Tier 1 condition education, privacy and nondiscrimination laws, Behavioral 
Risk Factor Surveillance System (BRFSS) genomics questions, and frequent 
collaborations with outside entities.  These results provide clear ideas to increase CDDs 
knowledge and interest in chronic disease genomics and potentially impact Tier 1 





Paths to Tier 1 Genomics Implementation: A Survey of Chronic Disease Directors 
by 
Amy H. Ponte 
 
MPH, University of Connecticut, 2000 
BS, Quinnipiac University, 1985 
 
 
Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 











 I would like to dedicate this dissertation to my family, specifically my husband, 
Peter, without whom I could not have accomplished this goal. This was my dream, 
something I knew I wanted to attain shortly after obtaining my master’s degree and raised 
my hand for once I went back to work after raising my kids and felt stuck professionally; 
I knew I could do more. Living my dream, however, required sacrifice not only for me 
but for everyone who was close to me. Sacrifice came in the form of less time together, 
missed events, fewer finances, more chores, and having to deal with my stress level to 
complete this dissertation and degree. I couldn’t have done it without all of them, 
including my kids, Patrick, Colleen, and Ana, who were always rooting me on and can 
now see what is possible. My example shows them that you’re never too old to learn 




 I would like to thank my chair, Dr. Ji Shen, for being the absolute best chair a 
student could have. I’m glad I hounded him for over two years to take me on. He was 
always there when I needed him and was able to back me off the ledge more than once 
when I was starting to get worried about progression or even if I had a clue about what I 
was doing. I would also like to thank Dr. Nicolette Alexander for her knowledge and 
expertise towards this project and for jumping into the middle of this; the transition was 
seamless. Furthermore, I would like to recognize Dr. Diana Naser, the Walden University 
Research Reviewer, for her diligent work on my study. I would also like to thank the 
APHA Genomics Forum policy subcommittee for allowing me access to the survey data 
used in this dissertation. Finally, I would like to thank all the mentors I’ve had throughout 
my life who fostered my love of science and my particular passion for genomics and its 
potential for better health of the human population. 
 I would be remiss if I didn’t thank the one who actually makes this all happen. 
This isn’t my doing, it’s only by the will of God that I got through this and get through 










Table of Contents 
List of Tables………………………………………………………….………….v 
List of Figures………………………………………………………………….....vii 
Chapter 1: Introduction to the Study ........................................................................1	  
Introduction ........................................................................................................1	  
Background ........................................................................................................2	  
Problem Statement .............................................................................................4	  
Purpose of the Study ..........................................................................................6	  
Research Questions and Hypothesis ..................................................................6	  
Theoretical Framework ......................................................................................8	  
Nature of the Study ............................................................................................9	  
Definition of Terms ..........................................................................................10	  




Implications for Social Change ........................................................................14	  
Summary ..........................................................................................................14	  
Chapter 2: Literature Review .................................................................................16	  
Introduction ......................................................................................................16	  
Literature Search Strategy ................................................................................17	  




Rogers’s Theory .........................................................................................18	  
How Roger’s Theory Has Been Used in Previous Research .....................20	  
Roger’s Theory and Public Health Genomics ...........................................21	  
History of Public Heath Genomics ..................................................................24	  
How Public Health Genomics Fulfills the Core Public Health Functions .26	  
The Role of Genomics in Population Heath ..............................................28	  
Family Health History ................................................................................29	  
From Precision Medicine to Precision Public Health ................................30	  
Tier 1 Genetic Testing Recommendations .......................................................31	  
Tier Classifications ....................................................................................31	  
Public Health Burden of Tier 1 Conditions ...............................................33	  
Description of Tier 1 Conditions ...............................................................35	  
Implementation of Tier 1 Tests: Current Landscape .......................................38	  
Examples of Cancer Genomics Translation by Model States ....................40	  
National Resources for State Public Health Genomics ..............................41	  
The Role of State Chronic Disease Departments in Tier 1 
Implementation ..............................................................................41	  
Challenges and Opportunities ..........................................................................43	  
Implementation Barriers ............................................................................43	  
The Need for Collaboration .......................................................................45	  
Summary and Conclusions ..............................................................................47	  





Research Design and Rationale .......................................................................49	  
Methodology ....................................................................................................52	  
Population ..................................................................................................52	  
Sampling and Sampling Procedures ..........................................................52	  
Procedures for Recruitment, Participation, and Data Collection ...............53	  
Instrumentation and Operationalization of Constructs ..............................53	  
Research Question 1 Variables ..................................................................56	  
Research Question 2 Variables ..................................................................56	  
Data Analysis ...................................................................................................58	  
Research Question 1 ..................................................................................58	  
Research Question 2 ..................................................................................59	  
Threats to Validity ...........................................................................................61	  
Ethical Procedures .....................................................................................62	  
Summary ..........................................................................................................63	  
Chapter 4: Results ..................................................................................................65	  
Introduction ......................................................................................................65	  
Data Collection ................................................................................................65	  
Survey Results .................................................................................................66	  
State Activities ...........................................................................................67	  
Frequency of Collaborations ......................................................................70	  




Data Analysis Results ......................................................................................74	  
Research Question 1 ........................................................................................74	  
Chi-Square .................................................................................................74	  
Independent t test .......................................................................................75	  
Multiple Linear Regression ........................................................................77	  
Research Question 2 ........................................................................................77	  
Chi-Square .................................................................................................78	  
Independent t test .......................................................................................80	  
ANOVA .....................................................................................................82	  
Multiple Linear Regression ........................................................................85	  
Pearson’s Correlation Coefficient ..............................................................85	  
Summary ..........................................................................................................87	  
Chapter 5: Discussion, Conclusions and Recommendations .................................90	  
Introduction ......................................................................................................90	  
Interpretation of Findings ................................................................................91	  
Using Rogers’ Theory to Diffuse Chronic Disease Genomics in More States 94	  
Limitations of the Study ...................................................................................95	  
Recommendations ............................................................................................96	  








List of Tables 
Table 1. Current Status of Chronic Disease Public Health Genomics Programming           
Adoption…………………………………………………………………………22 
Table 2. Role of Genomics in the Delivery of Essential Public Health Services..………27 
Table 3. Tier Classification System of Genomic Tests…………………………………..32 
Table 4. Public Health Prevalence and Burden of Tier 1 Conditions……………………34 
Table 5. Operationalization of Variables for Research Question 1………………….…..56 
Table 6. Operationalization of Variables for Research Question 2……………………...57 
Table 7. State Genomics Activities ……………………………………………………...69 
Table 8. Frequency of Collaborations or Partnerships Related to Genomics with Outside 
Entities…………………………………………………………………………...70 
Table 9. Agreement with Genomic Statements Regarding Importance of Genomics…...72 
Table 10. Level of Interest in Incorporating Genomic Activities………………………..73 
Table 11. Presence of State Genomic Funding vs. Knowledge or Interest of Genomic 
Topics…….....………………………………………………………………...…76 
Table 12. Presence of State Activity vs. Knowledge of Genomic Referrals or 
Consultations- “Don’t Know” included……………………………………...…. 79 
Table 13. Presence of State Activity vs. Knowledge of Genomic Referrals or 
Consultations “Don’t Know” changed to “No"……………………………...…..80 





Table 15. State Genomic Activities vs. Level of Knowledge or Interest of Genomic 
Topics “Don’t Know” changed to “No” ………………..……………………….81 
Table 16. State Genomic Activities vs. Level of Knowledge or Interest of Genomic 
Topics “Don’t Know” included……………………………………………...…. 83 
















List of Figures 
Figure 1. Survey Representation by Region ……………………………………………67 
























Chapter 1: Introduction to the Study 
Introduction 
The completion of the Human Genome Project in 2003 opened many doors for 
scientists and health professionals to identify and potentially prevent common disorders 
through gene analysis. Over the last decade, this progress has not only impacted clinical 
medicine and individual patients but has also shown the ability to reduce morbidity and 
mortality of susceptible populations through more personalized public health 
programming (Auffray et al., 2016; Cragun, Lewis, Camperlengo, & Pal, 2016). 
Unfortunately, translation and implementation of genomic advances has been slow, both 
in clinical medicine and public health (National Academies of Sciences, Engineering, 
2016). Most research in this area has been focused on implementation in the clinic; 
however, evidence supports the use of genomic technology for population-wide chronic 
disease prevention. Therefore, gaining an understanding of the opportunities and 
challenges to public health genomic implementation is prudent at this time. 
In this study, I conducted a quantitative survey of state and territorial chronic 
disease directors (CDDs) in the United States to examine what genomic activities are 
currently being achieved and determine if there is an association between these state 
activities and what these CDDs know or are interested about in chronic disease genomics. 
This study was important at this time because of recent evidence-based recommendations 
for screening at-risk individuals and their family members for hereditary forms of three 
chronic diseases; breast cancer, colon cancer, and cardiovascular disease. Identification 





reduce the morbidity and mortality from these conditions and allow for positive social 
change through increased health and quality of life for those affected. 
This introduction to the study will include background information leading to the 
current landscape, the purpose of this study and why it is important, and a description of 
the problem. I will also provide an explanation of the research questions and hypothesis, 
a description and justification of the theoretical framework, and outline the nature and 
significance of the study. Finally, I will define terms specific to this study and clarify the 
study’s assumptions, scope, delimitations, and limitations. 
Background 
The Healthy People 2020 initiative has included genomic activities for the first 
time, signifying increasing evidence that family history and genetic testing can be used to 
promote health benefits in clinical and public health capacities (Valdez, Yoon, Qureshi, 
Green, & Khoury, 2010; Weir et al., 2015). State public health genomics activities have 
traditionally been focused on newborn screening (NBS); however, evidence and test 
availability has prompted recommendations for adult population screening initiatives 
(Green, Dotson, Bowen, Kolor, & Khoury, 2015). The expansion of public health 
genomics from newborn screening into chronic disease is important and timely 
considering the impact of new molecular technology and research advances in the field 
(Bowen, Kolor, Dotson, Ned, & Khoury, 2012). Pilot public health genomics programs in 
chronic disease have showed that advances can be made by conducting evaluations and 
examinations that support use of genomic information and family history for disease 





and circulating educational materials for health care providers, policy makers, and the 
public (St Pierre et al., 2014).  
The last time a survey of state genetic activities was performed was in 2001 
(Coalition of State Genetics Coordinators, 2002; Piper et al., 2001). Also at that time, 
Kaye et al. (2001) made very specific recommendations regarding the need for the 
integration of genetics into public health and how genomic activities were connected to 
the core functions of assessment, assurance, and policy development. These authors also 
provided the rationale for and details of responsibilities for a state genetics coordinator 
position in order manage activities and facilitate collaborations in genomics. Another 
analysis of the role of genetics in the provision of essential public health functions found 
that these programs provide for many public health obligations including diagnosing and 
investigating health problems and hazards in the community (NBS), mobilizing 
community partnerships with genetics professionals and other health care providers, and 
linking the population to needed personal health services (Wang & Watts, 2007). 
Although these studies support the use of genomics as a public health tool outside 
of NBS, implementation beyond the pilot programs has been slow. In 2010, the 
Association of State and Territorial Health Officials (ASTHO) published a State Public 
Health Genomics Resource Guide outlining novel approaches for public health 
departments to translate genomic science into public health practice using examples from 
a limited collection of states with innovative programs (ASTHO, 2010). Although this 
toolbox was created to help other states find ways to integrate genomics into public 





diseases at the state level is not supported. A 2006 survey of state health officers 
confirmed important emerging public health functions; however, genomics was not one 
of them (Beitsch, Brooks, Grigg, & Menachemi, 2006). Moreover, a 2011 survey of 
chronic disease public health professionals about their training needs did not include any 
questions about genomics (Wilcox, Majestic, Ayele, Strasser, & Weaver, 2014). Until 
public health practitioners begin to think about genomics as a viable tool for public health 
prevention, implementation of state programs will likely not become a priority. This 
study was needed at this time to assess the current status of knowledge and interests in 
genomics by state CDDs and identify opportunities and challenges to increasing 
awareness of the importance of genomics by this group in light of the new chronic 
disease genomic testing recommendations.  
Problem Statement 
The Centers for Disease Control and Prevention (CDC) Office of Public Health 
Genomics (OPHG), the U.S. Preventive Services Task Force (USPSTF), and others have 
evaluated evidence and formulated recommendations for hereditary forms of chronic 
disease conditions that would benefit from patient genetic counseling, testing, and 
cascade screening of family members (Dotson et al., 2014). These applications are 
divided into a three-tier classification system with Tier 1 genomic applications having 
clear evidence for practical implementation (Khoury, Coates, & Evans, 2010). Initial 
Tier1 applications have been identified as hereditary breast and ovarian cancer (HBOC), 





Despite recommendations and evidence to support screening for these conditions, only a 
limited number of states are working in this area (Green et al., 2015). 
Federal funding from the CDC OPHG and the Division of Cancer Prevention and 
Control (DCPC) to support state chronic disease genomics infrastructure development, 
surveillance activities, and implementation of evidence-based recommendations has been 
limited to a small number of states since 2003: Michigan, Minnesota, Oregon, Utah, 
Connecticut, Colorado, Georgia, and Ohio (CDC, 2016; Green et al., 2015; St Pierre et 
al., 2014). Furthermore, to date, most implementation strategies have been focused 
specifically to address initiatives in HBOC, less often on LS, and limited activity on FH. 
((Laufman, Duquette, & Trepanier, 2012; Nordestgaard et al., 2013; Trivers, Rodriguez, 
Cox, Crane, & Duquette, 2015). Other states, such as Washington, Hawaii, Illinois, and 
New York, have made incremental strides in state genomics planning without CDC 
funding ((ASTHO, 2010; Trivers et al., 2015)).  
The ability to utilize these evidence-based initiatives under the current climate 
could be problematic and negatively impact our public’s health if citizens have limited 
access to these screening programs. Although studies have shown that chronic disease 
departments are hindered by poor collaborations, shifting goals, lack of organizational 
support, limited resources, alternating priorities, and competency by the public health 
workforce (Allen et al., 2013; Alongi, 2015), understanding and leadership by CDDs 
could also impact program implementation. Examining this group to evaluate their 
knowledge and interests in genomics is important in order to assess their ability to engage 





establishing an association between certain current state genomic activities and the 
knowledge and interests of CDDs could provide the evidence needed for increased 
coordination and funding to the states.    
Purpose of the Study 
The purpose of this quantitative survey design was to determine whether there is 
an association between current state genomics funding or specific state genomic activities 
and the level of knowledge and interests in genomics by state CDDs. In this quantitative 
survey design study, I analyzed the results of a survey of CDDs in all U.S. states and 
territories. My intent with this study was to identify and describe particular activities or 
particular states that may be associated with an increased level of knowledge and interest 
in genomics by CDDs and which may also influence implementation of Tier 1 genetic 
tests at the state level.   
Research Questions and Hypothesis 
Research Question 1: To what extent, if any, is there an association between states 
that have received funding for chronic disease genomics and the level of knowledge and 
interests in genomics by state and territorial CDDs? 
H01: There is no association between states that have received funding for chronic 
disease genomics and the level of knowledge and interests in genomics by state and 
territorial CDDs. 
H11: There is an association between states that have received funding for chronic 






Research Question 2:  To what extent, if any, is there an association between 
current state genomic activities and the level of knowledge and interests in genomics by 
state and territorial CDDs? 
H02: There is no association between any current state genomic activities and the 
level of knowledge and interests in genomics by state and territorial CDDs. 
H12: There is an association between one or more current state genomic activities 
and the level of knowledge and interests in genomics by state and territorial CDDs. 
Current state genomic activities that were seen as having a potential impact on 
chronic disease public health genomics program implementation were queried. These 
included (a) a state genetics needs assessment, (b) a state genetics needs assessment that 
includes chronic disease conditions, (c) inclusion of genetics in the state public health 
action plan, (d) genetic educational programs, (e) genomics topics on the BRFSS, (f) 
analysis of state cancer registries or other vital records data to identify citizens with 
hereditary cancer syndromes, (g) frequency of collaborations or partnerships with outside 
entities related to genomics, and (h) presence of legislation and/or regulation specifically 
related to genomics. To determine the knowledge and interests in genomics by the CDDs, 
they were asked about their (a) awareness of contact information for clinical genetic 
services for potential referral or consultation, (b) knowledge of Tier 1 recommended 
conditions, (c) agreement with genomic statements, and (d) interest in the integration of 






In this study, I used the theoretical framework of the diffusion of innovations 
theory to explore the adoption of chronic disease genomics at the state level. According 
to Rogers (2003), adoption of new innovations in organizations can be challenging even 
if the advancements have clear, evidence-based rewards as in the current climate of Tier 
1 recommendations. Diffusion is a process that occurs over time through communication 
between members of a social system and culminates with a modification of the structure 
and function of the social system (Rogers, 2003). The four main elements of this theory 
include the characteristics of the innovation itself, communication channels, time, and a 
social system that supports adoption (Rogers, 2003) 
 In this study, I examined the social system that supports adoption of chronic 
disease genomics, particularly looking at specific state genomic activities that may be 
associated with the level of knowledge and interests in genomics by CDDs. Moreover, 
based on Roger’s (2003) theory, adoption of chronic disease genomics is ready to move 
into more states at this time; I will discuss this topic in more detail in Chapter 2. This 
adoption could be connected to genomic champions who have worked to secure funding 
for genomic activities in their states. My determination of whether or not there was an 
association of greater knowledge and interests in genomics by the CDDs in the few states 
that have received funding could influence the need to identify a genomic champion in 





Nature of the Study 
In this study, I used a nonexperimental, cross-sectional, correlational quantitative 
survey design to examine current state genomic activities and possible associations with 
the level of knowledge and interests in genomics by CDDs from all U.S. states and 
territories. This survey was originally developed by a subcommittee of the American 
Public Health Association (APHA) Genomics Forum Policy Committee (GFPC), of 
which I am a member, in order to determine opportunities and challenges of state CDDs 
in genomics and possibly create a position statement by the APHA. The survey design 
was chosen because it would be fairly easy to administer to the study group via e-mail 
web-link, be simple to develop at little or no cost, and could ask a number of pertinent 
questions to obtain a broad range of data (see Frankfort-Nachmias & Nachmias, 2008).  
 With the first half of the survey, I collected information about the presence of 
specific state genomic activities and in the second half inquired about knowledge and 
interests in genomic topics among CDDs. State genomic activities were either present 
(Yes), absent (No), or unknown (Don’t know). One question was framed to inquire about 
frequency of collaborations with outside entities and was measured on a Likert scale. 
Knowledge and interests about genomic topics were also measured on a Likert scale; 
however, these results were converted to a numerical product for analysis of the level of 
knowledge or interest (e.g. Agreement with genomic statements: 1= strongly disagree 
through 5= strongly agree). I performed statistical analysis to determine the relationship 
between the variables to see if state funding or any particular activity was associated with 





Definition of Terms 
I am providing the following definitions to ensure uniformity and understanding 
of these terms throughout the study: 
Cascade screening: The systematic identification and testing of family members 
of an individual who has a particular disease of interest (Ned & Sijbrands, 2011). 
Diffusion: The process by which an innovation is communicated through certain 
channels over time among members of a social system (Rogers, 2003). 
Evidence-based medicine: Health technologies and practices supported by sound 
research evidence (Greenhalgh, Robert, Macfarlane, Bate, & Kyriakidou, 2004) 
Genetics: The study of heredity with a focus on a specific and limited number of 
genes with known function in disease (Manolio, 2016). 
Genomics: The study of an individual’s entire genetic makeup, the genome, while 
also examining how the genome interacts with environmental or behavioral factors. This 
is especially important in the study of complex chronic diseases that affect large factions 
of the population (Cragun et al., 2016)  
Innovation: A novel set of behaviors, routines, and ways of working, which are 
directed at improving health outcomes, administrative efficiency, cost-effectiveness, or 
user experience, and which are implemented by means of planned or coordinated action 
(Greenhalgh, Robert, & Bate, 2005). 
Precision medicine:  Tailoring medical therapies to subcategories of disease based 





Precision public health: Providing the right intervention to the right population at 
the right time (Khoury, Iademarco, & Riley, 2016). 
Public health genomics: The study and application of knowledge about the 
elements of the human genome and its functions, including interactions with the 
environment, in relation to health and disease in populations (Cleeren, Van der Heyden, 
Brand, & Van Oyen, 2011). 
Scope and Delimitations 
The scope of this study consisted of all state and territorial CDDs in the United 
States. To date, this group had not been surveyed specifically about knowledge in 
genomics and its connection to chronic disease nor the possible association with current 
state genomic activities.  Each state and territory has one director and all are members of 
the National Association of Chronic Disease Directors (NACDD), which was my point of 
contact and access to this study group. The total possible participants for this study was 
58, and each chronic disease director had an equal chance to participate in this study. To 
encourage participation, I limited the quantitative survey design to mostly closed-ended 
questions and took place in a 6-week timeframe.  
I explored a range of theoretical models to provide a framework for this study. 
Consideration was given to the transformational leadership and transtheoretical models, 
utilization management, attribution, and complex adaptive theories. Upon discussion with 
my committee, I decided to use Rogers’ diffusion of innovations theory to explain the 






One assumption I made in this study was that the database provided for the target 
population by the NACDD was current and accurate. The CEO of the NACDD explained 
that the database is updated yearly and frequent e-mails are sent each month ensuring 
accuracy (J. Robitscher, personal communication, January 5, 2017). Another assumption 
was that the sample of survey responses is representative of the whole population of 
CDDs being studied. Because one question on the survey asked about what state the 
chronic disease director practices in, this helped determine if the study population resided 
in different parts of the country (heterogeneous sample) or from states that have received 
some type of funding for state genomic activities related to chronic disease. A final 
assumption was that respondents answered the questions truthfully. As this is a 
confidential, voluntary questionnaire, it would be more likely that these directors would 
be honest in their responses. 
Limitations 
Due to the small sample size available for the study, results may not be 
generalizable beyond the specific population from which the sample was drawn. Because 
the number of CDDs in the United States and territories is limited, a small response rate 
impacted the power of the analysis (< 80%) by introduction of Type II errors and not 
allowing for generalizability to the study population (Field, 2013). The nonresponse bias 
is also important; the nonresponse bias is how different or similar those who do not 
respond are from the whole survey population (Johnson & Wislar, 2012). Those who 





and vice versa. Also, because the subcommittee and I conducted this study voluntarily, 
there was no monetary compensation for the directors to complete the survey, which may 
have also impacted the response rate (Cho, Johnson, & VanGeest, 2013). This survey was 
a web-based instrument with a short completion time (6 weeks), which could have 
affected participation if the CDDs did not find the time or remember to complete it in the 
allotted window.  A final limitation was that, although this was a confidential web-based 
survey, this did not assure that the chronic disease director who received the survey was 
the one who completed it in part or in totality.  
Significance 
Data from this study could provide public health leaders at the federal, state, and 
local levels with information as to what specific genomic activities are associated with 
increased levels of knowledge and interest in genomics by state CDDs. This information 
could be starting point for states to increase genomic activities to conform to the new 
Healthy People 2020 objectives, Precision Medicine Initiative, and Tier 1 genetic testing 
and screening recommendations (Auffray et al., 2016; Dotson et al., 2014; Weir et al., 
2015). These results could also support and provide rationale for public and private 
funding for state genomic activities and identify states that are ready to begin genomics 
implementation. Finally, the results of this survey could provide a small snapshot of what 
is and is not being done in the states today in regards to genomics as well as highlight the 





Implications for Social Change 
Walden University defines positive social change as “a deliberate process of 
creating and applying ideas, strategies, and actions to promote worth, dignity, and 
development of individuals, communities, organizations, institutions, cultures, and 
societies” (Walden University, 2016, para. 2). This definition is expected to provide a 
foundation for student research that will result in the betterment of human and social 
conditions. In the context of this study, the implications for social change relate to the 
rights of the public to have access to evidence-based technology that has the ability to 
reduce morbidity and mortality of certain hereditary diseases. Gaining an understanding 
of the opportunities and barriers to Tier 1 chronic disease genomics implementation could 
provide the “ideas, strategies, and actions” for increasing this work in more states 
(Walden University, 2016, para. 2). If there is a connection between particular state 
genomic activities and how knowledgeable and interested the CDDs are in this area, this 
finding could encourage funding for more state activities. This funding could provide a 
ripple effect of engagement for chronic disease departments, state health departments, 
and other stakeholders.  
Summary 
Individuals who work in public health have a responsibility to ensure that the 
communities they serve are healthy by assuring safe, accurate, and accessible chronic 
disease genomic services (Cragun et al., 2016). Expansion of state chronic disease 
genomics to a larger proportion of states is prudent at this time in light of the Healthy 





genetic testing and screening recommendations (Auffray et al., 2016; Modell, Greendale, 
Citrin, & Kardia, 2016; Weir et al., 2015). The purpose of this study was to identify some 
possible opportunities and challenges to reach that goal. This foundation will support 
ideas to facilitate implementation of chronic disease public health genomics in more 
states. 
In this introduction, I presented the statement of the problem, research questions, 
definition of terms, scope, nature, and significance of the study, as well as study 
limitations. In Chapter 2, I will provide a review of the literature in the field of public 
health genomics from its inception to the present day and connect what is currently 
happening through Roger’s diffusion of innovations theory. I will outline the 
methodology and data collection procedures in Chapter 3 and describe the data analysis 
and findings in Chapter 4. Finally, Chapter 5 will include my summary and discussion of 














Chapter 2: Literature Review  
Introduction 
The problem I addressed with this study was the need for public health genomic 
programming to move beyond traditional NBS and into the chronic disease arena in the 
United States and its territories (Bowen et al., 2012). Current evidence is available to 
encourage genomic risk assessment through the screening and testing of individuals and 
cascade follow-up and testing of at-risk family members for hereditary forms of breast, 
ovarian, and colon cancer as well as cardiovascular disease (Dotson et al., 2014). Public 
health practitioners, especially at the state level, are poised to be the leaders in facilitating 
evidence-based genomic surveillance and screening for certain hereditary chronic 
diseases (Green et al., 2015).  
This chapter will include a narrative of the birth of public health genomics 
through the present day including how public health genomics ties into the core public 
health functions, the role of genomics in population health, a definition of precision 
public health, Tier 1 genetic testing recommendations, and the burden of each condition. 
Finally, I will describe the role of state chronic disease departments in Tier 1 
implementation and the current landscape. Through my review and discussion of the 
literature on the framework of this study, Rogers’ diffusion of innovations theory, I will 
demonstrate where public health genomics is today and how it is poised to move to the 
next level, what translation barriers exist, and how collaboration is crucial to 





The purpose of this quantitative survey design was to determine whether there is 
an association between current state genomics funding or specific state genomic activities 
and the level of knowledge and interests in genomics by state CDDs. Using this 
quantitative survey design, I analyzed results of a survey of CDDs in all U.S. states and 
territories. The intent of this study was to identify and describe particular activities or 
particular states that may be associated with an increased level of knowledge and interest 
in genomics by CDDs, which may also influence implementation of Tier 1 genetic tests 
at the state level.   
Literature Search Strategy 
I conducted a review of the literature using the Walden University Library, 
Google Scholar, and the World Wide Web. I searched the CINAHL, 
MEDLINE/PubMed, Science Direct, EBSCO, and ProQuest Central databases for peer-
reviewed, English language journal articles focusing on articles of interest in the last 5 to 
6 years (2010–2016). Key search terms used included public health, genetics or 
genomics, chronic disease directors, knowledge of genomics, population genomics, 
champion, and diffusion of innovations. These searches yielded 326 scholarly journal 
articles, four books, and two dissertations related to the topic of this study.  
Theoretical Foundation 
At the time of this study, very few states are doing any significant work in chronic 
disease public health genomics with a majority of states incorporating these activities on 
a limited basis and predominantly focusing on the core function of assurance (Laufman et 





important role in the diffusion of these new evidence-based public health applications by 
modeling activities, providing public health outcome data, and championing the cause as 
an opinion leader or change agent. In this literature review, I investigated how Rogers’ 
diffusion of innovations theory could be used to explain the development of the field of 
chronic disease public health genomics and ways that this theory could be used with the 
results of this study to identify clear avenues to increase adaptation across more states 
throughout the country. 
Rogers’s Theory 
Diffusion is “the process by which an innovation is communicated through certain 
channels over time among members of a social system” (Rogers, 2003, p. 5). The four 
main components are (1) the innovation, (2) communication channels, (3) time, and (4) 
the social system. An innovation is a new idea that will likely bring forth a certain degree 
of uncertainty to the social system depending on the number of alternatives available and 
the probability that the new innovation is superior to or enhances current practices 
(Rogers, 2003). Communication of the benefits of the new innovation is a two-way 
process that occurs over many cycles of information exchange to reach a mutual 
understanding (Rogers, 2003). Time is an important component of the diffusion process 
whether to understand the innovation decision process from first knowledge to 
acceptance or rejection, why certain individuals adopt the innovation earlier or later in the 
process, and the innovation’s rate of adoption in a system (Rogers, 2003). Finally, 





new idea is conceived, diffused, and either incorporated or rejected leading to 
consequences that change the social system (Rogers, 2003). 
The five adopter categories are (1) innovators, (2) early adopters, (3) early 
majority, (4) late majority, and (5) laggards (Rogers, 2003). Innovators, the first to adopt 
a new idea into a system, actively seek new ideas, often reach outside their own locale for 
information and support, and are able to handle greater amounts of uncertainty (Rogers, 
2003). These individuals often serve as change agents who influence others in the social 
system to adopt the innovation (Rogers, 2003). 
Early adopters are also enthusiastic about new innovations while still being 
selective about what they adopt (Rogers, 2003). This group also has a great degree of 
opinion leadership; however, they examine both the positive and negative aspects of an 
innovation, so buy-in from this group is critical to adoption success (Rogers, 2003). 
These individuals are often consulted by others for advice and information about the 
innovation, serve as role models, and help decrease uncertainty by others (Rogers, 2003). 
The early majority adopts new innovations before the average members of the system; 
however, adoption comes only after lengthy deliberation (Rogers, 2003). This group is an 
important link to the diffusion process by connecting the enthusiastic leaders with the 
typical members of the group who are inclined to be more resistant to adoption (Rogers, 
2003). 
The late majority are skeptical and only adopt innovations due to economic or 
system pressures even after they have been persuaded of the utility of the new idea; most 





(Rogers, 2003). Finally, laggards are the last to adopt a new innovation because they 
traditionally live in the past, are resistant to change, and are suspicious of new ideas 
(Rogers, 2003). Rogers (2003) explained that by the time laggards adopt a new 
innovation, it may already be out of date and surpassed by a newer method. 
How fast an innovation is adopted by the members of a social system is 
contingent on its perceived characteristics, type of innovation decision and 
communication channels used, inherent nature of the social system, and the extent of 
effort by change agents in diffusing the innovation (Rogers, 2003). The diffusion effect 
explains the important relationship between the rate of knowledge about an innovation 
and the rate of its adoption by those in the system (Rogers, 2003). As the level of 
innovation knowledge increases to the 20–30% range, only small amounts of adoption 
occur; however, once this threshold passes the tipping point (which can be slightly 
different depending on the innovation and system), the rate of adoption increases 
exponentially (Griliches, 1957). This threshold is often contingent on the point at which 
opinion leaders in a system begin to look favorably on the innovation and activate peer 
networks in the social system.   
How Roger’s Theory Has Been Used in Previous Research 
 According to Schon (1963), resistance to change is normal and may also seem 
desirable in many instances to assure stability in organizations. In order to promote 
changes that are in the best interests of the organization and those they serve, a champion 
will often emerge to fight for the introduction and development of a new innovation. 





effective at influencing the leadership process to produce the desired change (Taylor, 
Cocklin, Brown, & Wilson-Evered, 2011). Champions are intrinsically motivated, 
energetic and enthusiastic, and committed to the cause; either the new advancement finds 
a champion or dies (Schon, 1963). 
 Previous researchers have examined the use of champions on diffusion of 
innovations in health care settings. A 2006 study on the implementation of the MOVE! 
weight-management program in the Veteran’s Health Administration found that 
organizational readiness for change and the presence of an innovation champion were key 
factors in the success of this program (Weiner, Haynes-Maslow, Kahwati, Kinsinger, & 
Campbell, 2011). Novick et al. (2015) also found that champions who advocated for the 
enactment of a new model for prenatal care were instrumental in successful 
implementation and sustainability at group practices. Finally, a study about the adoption 
of the Agency of Healthcare Research Quality tools to assess pharmacy’s health literacy 
practices also found that a change champion would have a positive impact (Shoemaker, 
Staub-DeLong, Wasserman, & Spranca, 2013).  
Roger’s Theory and Public Health Genomics 
The field of public health genomics outside of NBS has seen some great successes 
in model states since the establishment of the Office of Public Health Genomics at the 
CDC in 1997, the completion of the Human Genome Project in 2003, and the 
formalization of the field in 2005 (Green et al., 2015; Modell et al., 2016). These model 
states have all received some kind of funding for genomic activities and assessments 





2015) Table 1 shows the model states and their category of adoption. At this time, the 
field appears to be at or over the tipping point and is ready for integration of chronic 
disease genomics into more states (19–20) in the early majority category.  
Table 1    
Current Status of Chronic Disease Public Health Genomics Programming Adoption 




Innovators 2.5% 1–2 Michigana,b,c 
   Oregona,b,c 
Early Adopters 13.5% 7–8 Connecticuta,b,c 
   Utaha,b,c 
   Minnesotaa,b 
   Georgiaa,b 
   Coloradoc,d 
   Ohioa 
   Washingtone 
Early Majority 34% 19–20  
Late Majority 34% 19–20  
Laggards 16% 9–10  
Note. (a) St Pierre et al., 2014, (b) Green et al., 2015 (c) CDC, 2016, (d) ASTHO, 2011a,  
(e) ASTHO, 2011b. 
Innovativeness refers to how quickly or reluctantly an individual or system unit 
adopts an innovation (Rogers, 2003). New innovations are often proposed by opinion 
leaders, such as the OPHG, who maintain a high degree of credibility regarding the 
technical and theoretical aspects of the innovation (Rogers, 2003). Change agents, who 





adoption of an innovation (Rogers, 2003). In this case, the change agents would 
champion the diffusion of chronic disease genomics at the state level. 
One area that has been shown to impact an innovation’s adoption is the 
communication and influence that occurs through social networks, peer and expert 
opinion, champions, and change agents (Greenhalgh et al., 2004). Currently, model states 
that are doing work in chronic disease public health genomics have at least one individual 
who devotes time to initiate agendas, develop and assess programs, seek and obtain 
funding, provide education, and facilitate stakeholder collaborations (ASTHO, 2010; St 
Pierre et al., 2014). As Rogers (2003) explained, the “presence of an innovation 
champion contributes to the success of an innovation in an organization” through 
communication of the benefits of an innovation over a period of time and numerous 
conversations to influence the rate of adoption (p. 414). Schon (1963) clearly stated that 
without a champion, new ideas will likely die from normal and somewhat desirable 
resistance to change. Having a genomic champion at the state level that is knowledgeable 
and committed to chronic disease genomics could positively impact the rate of adoption 
of genomics in state health departments.  
Although evidence exists to support chronic disease genomics in the states, only a 
handful of states are working to that end. Diffusion of this new innovation and the rate of 
adoption by more states can be encouraged by a variety of factors such as the level of 
communication and influence provided to stakeholders, which includes state and 





who has likely impacted the rate of adoption in their states and this can be a model to 
increase implementation in additional states. 
History of Public Heath Genomics 
In 1990, the National Institutes of Health and Department of Energy launched the 
Human Genome Project to develop technology that could analyze DNA, map and 
sequence the human genome, and investigate associated ethical, legal, and social issues 
(National Human Genome Research Institute (NHGRI), 2015). In order to address the 
population health impact of the HGP, the CDC established the Office of Genetics and 
Disease Prevention (now the OPHG) and created a strategic plan to address the 
translation of genomic advances into population health (Zimmern & Khoury, 2012). 
Since its inception in 1997, the OPHG has involved many partners to anticipate, evaluate, 
and demonstrate the translation of genomics into population health practices (OPHG, 
2011). A meeting in Bellagio, Italy in 2005 resulted in the formal definition of public 
health genomics as “a multidisciplinary field concerned with the responsible and 
effective translation of genome-based knowledge and technologies into health care 
practices to improve population health” (Bellagio Report, 2005; CDC, 2007, p. 1). Public 
health genomics seeks to use population data of genetic variation and environmental 
influences to establish evidence-based interventions for disease prevention and health 
improvement.  
Use of genome-based knowledge for public health interventions has been around 
long before the term public health genomics was first defined. In 1961, Dr. Robert 





the institution of mandatory state screening programs in 1963 (NHGRI, 2016). Today, 
virtually all babies born in the United States undergo NBS in state run programs to detect 
a variety of endocrine, metabolic, and hematologic conditions that are genetic in nature 
and was named one of the 10 Great Public Health Achievements of the 20th century 
(CDC, 2011; Ross, 2010). Universal screening of newborns highlights the ability of 
public health to reduce morbidity and mortality of hereditary conditions through state-run 
programs. 
Recently, there has been increasing momentum from the national level to 
encourage the integration of genomics into public health programming. In December of 
2010, the Office of Disease Prevention and Health Promotion included genomics in the 
Healthy People 2020 objectives for the first time (Office of Disease Prevention and 
Health Promotion, 2016). These new objectives reflect increasing evidence to support the 
use of genetic tests and family health history in clinical medicine and public health. The 
first two recommendations include (a) Women with a high familial risk of breast, 
ovarian, tubal, or peritoneal cancer could benefit from genetic counseling to learn more 
about genetic testing for the breast cancer susceptibility gene (BRCA) 1/2 mutations and 
post-test surgical options to reduce risk, and (b) All newly-diagnosed colorectal cancer 
patients should receive information regarding genetic testing to identify a hereditary form 
of this cancer (LS), which could benefit family members by reducing their risk of 
colorectal cancer caused by LS through screening and interventions.  
In January 2015, President Obama announced his support for the Precision 





disease prevention and treatments based on individual differences in genetics, 
environment, and lifestyle (The White House, 2015). His $215 million, 2016 budget 
financing is to be a collaborative public and private investment in genomic advances, 
tools for managing and analyzing large sets of data while protecting patient privacy, and 
health information technology. This initiative is also designed to engage at least a million 
Americans to volunteer their health information to study health outcomes, develop new 
treatments, and introduce a more precise and personalized healthcare system. Of course, 
all of these promises are at-risk under the new administration. 
How Public Health Genomics Fulfills the Core Public Health Functions 
The mission of public health is “fulfilling society’s interest in assuring conditions 
in which people can be healthy” (Institute of Medicine Committe for the Study of the 
Future of Public Health, 1988, p. 7). This mission is to be carried out through public and 
private partnerships, however, public agencies have a responsibility to assure that 
essential components are in place to address the mission effectively. Along with that 
mission are three core public health functions; assessment which includes collection and 
analysis of population health data, assurance of quality services to all, and policy 
development based on sound scientific knowledge and use of the democratic political 









Table 2   
Role of Genomics in the Delivery of Essential Public Health Services 
Core Function Description Examples 
Assessment Monitor Health 
Diagnose & 
Investigate 
•   Utilize family history or genetic testing to 
identify at-risk individualsb 
•   Perform epidemiologic studies on the 
prevalence of genetic risks factors / 
variants within the community to 
determine their contribution to identified 
health problemsa  
•   Study gene-gene and gene- environment 
interactionb 
•   Assess the availability, appropriateness, 
and accessibility of quality genetics 
resources in the communitya 
•   Assess the impact of genetic information 
and its value in improving healtha 
•   Research the community’s and health care 
providers’ knowledge of the use of 
genetics to improve healthc 








•   Collaborate with other public and private 
entities and educate public health staff and 
private health-care workers about the use of 
genetic information to improve healtha 
•   Incorporate genomics into the curricula of 
medical schools, nursing schools, and 
schools of public health and provide 
opportunities for continuing education 
around genomicsb 
•   Evaluate genomic tests, services, and 
information to ensure availability, efficacy, 
accessibility, safety, quality, and ethical 
practices while also enforcing the policies 
and standards enacted to ensure thisb 
•   Identify and analyze the factors that 
influence the impact of genetic information 
and the delivery, utilization and quality of 







Core Function Description Examples 












•   Improve genomic literacy of the public, 
health care practitioners, policy makers, and 
other stakeholders through audience-
specific educational initiatives about the 
integration of genomics into health 
promotion and disease prevention 
programsb 
•   In collaboration with stakeholders, 
implement regulatory policies and 
guidelines for clinical applications, test 
implementation, use, impact, and protection 
of genomic information, and accessibility 
and quality of genomic technologya,b 
•   Identify and analyze the economic, social, 
ethical and political implications of 
advances in human genetics, including the 
information and communications needs of 
stakeholdersb 
•   Assure insurance coverage for high risk 
individualsb 
•   Develop, enhance and sustain partnerships 
with key partnersa 
Note: (a) Khoury, 2011, (b) McWalter & Gaviglio, 2015, (c) ASTHO, 2010. 
The Role of Genomics in Population Heath 
During the last 20 years, the OPHG at the CDC and other multidisciplinary 
groups have been trying to use the knowledge gained from the HGP and other scientific 
advances and translate this into activities for population health (Zimmern & Khoury, 
2012). Beyond the ever-expanding state universal newborn screening panels, public 
health genomics is going to play a significant role in epidemiological studies, infectious 
disease, chronic disease, and environmental health (Roberts, Dolinoy, & Tarini, 2014). 
Implications will also be felt in areas such as biostatistics, health policy and regulation, 
health education, health behavior responses to genomic information, and equitable 





integration of genomics into this wide variety of activities will require complex 
structures, processes, and collaborations by a diverse range of stakeholders to fully 
realize the translation of genomic findings into improved population health. 
Family Health History  
The original genomic tool used in medicine and public health has been the use of 
family health history (FHH). A large majority of chronic diseases of public health 
significance including diabetes, cardiovascular disease, several cancers, osteoporosis, and 
asthma have been shown to have a strong family history component (Yoon et al., 2002). 
FHH is a combination of shared genetic susceptibility, environment, and behaviors and, 
prior to the availability of genetic testing, chronic disease programs and clinical health 
practitioners have traditionally focused their efforts on the environmental and behavioral 
components (OPHG, 2011). Use of FHH and possible genetic screening and testing could 
complete a three-legged stool of disease prevention targets. Public health leaders can be 
effective advocates in educating others about the link between FHH and chronic disease, 
especially to minority groups, and can use this tool as a surveillance method to identify 
at-risk individuals and their family members, and evaluate the impact on population 
interventions (Butty et al., 2012; Khoury et al., 2011; Powell, Edleson, O’Leary, 
Christianson, & Henrich, 2011; Senier et al., 2015). Although FHH will continue to be a 
valuable primary prevention tool, issues with collection, standardization, interpretation, 
and integration with electronic health records exist and will need to be addressed (Bowen 





From Precision Medicine to Precision Public Health 
Precision medicine, sometimes referred to as personalized medicine, is a concept 
that implies prevention or treatments based on individual differences (Collins & Varmus, 
2015). Pharmacogenomics, the most recognized precision medicine mechanism, is aimed 
at providing the right drug to the right patient at the right time based on an individual 
patient’s genetic makeup (Auffray et al., 2016).  Precision public health, on the other 
hand, focuses on individuals within a defined population for “providing the right 
intervention to the right population at the right time” (Khoury, Iademarco, & Riley, 2016, 
p. 398). Long before advances in genomics, Rose (1985) explained that populations 
would be healthier and costs contained if prevention efforts were targeted at those in the 
population who are at greatest risk for an identified disease. Identifying and explaining 
why some individuals, or groups of individuals, get sick while others don’t is an excellent 
guide to public health prevention efforts. Targeted public health screening programs not 
only seek to protect susceptible individuals, but try to discover and control the cause of 
incidence; susceptibility will not exist if causes are removed or circumvented. 
The completion of the Human Genome Project has enabled a significant 
opportunity to practice clinical medicine and public health in a novel way. Acquiring the 
ability to identify disease in individuals and populations based on genetic components 
will permit us to target prevention efforts and treatments based on heredity and individual 
or population susceptibility. This has been highlighted by inclusion of genomics for the 
first time in the Healthy People 2020 objectives and support for the Precision Medicine 





supports delivery of essential health services, and will play an active role in furthering 
use of genomic advancements in population health. 
Tier 1 Genetic Testing Recommendations 
Due to advances from the Human Genome Project and genomic applications, 
evidence-based recommendations are now available to move public health genomics 
from reducing morbidity, mortality, and disability in the newborn period to identification 
of genetic influences across the lifespan (Bowen et al., 2012). Although a large 
proportion of applications will be delivered in the clinical care setting, state public health 
agencies are poised to be the leaders in targeted population screening programs (Khoury 
et al., 2011). These leaders will be responsible for program development and 
implementation, delivery, assessment, reduction of potential harms, equitable access, and 
creation of a multidisciplinary infrastructure for program support and future use of 
genomic applications. Public health professionals, who are focused on population health 
and reduction of health disparities, can successfully gather these stakeholders without 
bias or another agenda. 
Tier Classifications 
In 2005, the CDC OPHG established the Evaluation of Genomic Applications in 
Practice and Prevention (EGAPP) Initiative to develop a process for an evidence-based 
evaluation of genomic tests in clinical medicine and public health practice (Teutsch et al., 
2009). Recommendations for test readiness come from a multidisciplinary expert group 
of nonfederal, independent individuals who evaluate a test’s (a) analytic validity (ability 





to detect or predict the disorder or phenotype of interest); (c) clinical utility (evidence of 
improved measurable clinical outcomes and usefulness to patient management); and (d) 
associated ethical, legal, and social implications before suggesting its use (Green et al., 
2015; Secretary’s Advisory Committe on Genetic Testing, 2000). These tests have been 
classified into a three tiered, color-coded system to indicate what tests are ready to be 
integrated into clinical care and public health practice (Dotson et al., 2014; see Table 3). 
Table 3   
Tier Classification System of Genomic Tests 
Tier 1 Tier 2 Tier 3 
Genomic and Family 
Health History 
applications have a base of 
synthesized evidence to 
support integration into 
practice. 
Genomic and Family 
Health History applications 
have insufficient evidence 
to support routine 
implementation into 
practice. 
These applications do have 
the potential to provide 
information for informed 
decision making by 
patients and providers or 
for informing selective use 
strategies (e.g. clinical 
trails) through clinical or 
public health policy 
decision making. 
 
Genomics and Family 
Health History applications 
have evidence that either 
results in recommendations 
against use OR no relevant 
evidence is available at this 
time. Tier 3 applications are 
not ready for routine use 
but may be used for clinical 
or population research. 
Note. Adapted from Dotson, W. D., Douglas, M. P., Kolor, K., Stewart, a C., Bowen, M. 
S., Gwinn, M., … Khoury, M. J. (2014). Prioritizing genomic applications for action by 
level of evidence: A horizon-scanning method. Clinical Pharmacology and Therapeutics, 
95(4), 394–402. http://doi.org/10.1038/clpt.2013.226. 
As of April 2016, 46 tests have been classified as Tier 1, 105 are Tier 2, and nine 





pharmacogenomics, tests also include the 31 core newborn screening conditions and three 
chronic disease conditions.  Applications for these conditions include cascade DNA and 
LDL (low-density lipoprotein) testing of relatives of patients identified with FH, 
diagnostic screening for LS for colorectal cancer patients and cascade screening for their 
family members, and risk prediction and referral to genetic counseling for BRCA testing 
for those with a risk of HBOC.   
Classifications for these Tier 1 genomic applications are based on the 
recommendations of the National Institute for Health Care Excellence, EGAPP, and the 
U.S. Preventive Services Task Force (Evaluations of Genomic Applications in Practice 
and Prevention Working Group, 2009; National Institute of Health and Care Excellence, 
2008; U.S. Preventative Services Task Force, 2014). All three disorders are autosomal 
dominant (only one defective gene is required to inherit the disease); have lifelong health 
implications; and use family health history to identify those at risk and cascade screening 
to connect to family members who could benefit from further follow-up (Bowen et al., 
2012).  FH also includes a rarer homozygous variant (two mutations are inherited) which 
increases the severity of the disorder (Nordestgaard et al., 2013). 
Public Health Burden of Tier 1 Conditions 
There are over two million individuals who carry the mutational genes for HBOC, 
LS, and FH in the United States today (George, Kovak, & Cox, 2015). Considering that 
cancer and heart disease are currently the top two burdens in our health care system, 





and reduce the incidence of these diseases should be a key public health focus  (American 
Cancer Society, 2016; American Heart Association, 2015). At present, these conditions  
are poorly identified by the healthcare system so targeted Tier 1 genetic testing programs 
and potential cascade screening of family members implemented through state public 
health departments in collaboration with health care practitioners could offer significant 
reduction in health risks from these diseases and their associated costs (OPHG, 2014). 
Table 4 displays the potential impact of Tier 1 genetic testing on the conditions 
identified. 
Table 4 
Public Health Prevalence and Burden of Tier 1 Conditions 











cause of cancer 
death1 











of death in both 
men and 
women  
Estimated total new 








73.5 million  
in pop (31.4%) 
Prevalence of 
mutation in new 
cases 
2–7% 2a 10–15%2a 3–5%4 N/A 






















persons  N/A 
Risk of disease with 
mutation 40–80%
3 11–40%3 80%6 50% men – 30% women7 
Estimated 
prevalence of 
mutation in US 
population 



















Note: (a) Significantly higher rates in Ashkenazi Jewish population, (b) Based on calculation of total new 
cases and % new mutation prevalence. Does not include family members potentially identified through 
cascade screening, (c) Estimated higher rates in European Caucasian populations, (d) Based on estimated 
current U.S. population of 324 million (United States Census Bureau, 2016b). 
 
1. (American Cancer Society, 2016), 2. (D’Andrea et al., 2016), 3. (Petrucelli, Daly, & Feldman, 2013),  
4. (American Cancer Society, 2014), 5. (Hampel & De La Chapelle, 2011), 6. (Guillén-Ponce, Molina-
Garrido, & Carrato, 2012), 7. (National Organization for Rare Disorders, 2016), 8. (Ned & Sijbrands, 
2011), 11. (American Heart Association, 2015) 
 
Description of Tier 1 Conditions 
Hereditary breast and ovarian cancer (HBOC). HBOC syndrome is caused by 
mutations in the BRCA1 and BRCA2 genes, which not only cause an increased risk for 
breast (40–80%) and ovarian (11–40%) cancers, but also pancreatic and prostate cancers 
(Petrucelli et al., 2013). Mutations in BRCA 1/2 are passed in an autosomal dominant 





of these cancers is based on when the cancer is detected, so identification of increased 
susceptibility through genetic testing and subsequent preventative monitoring and/or 
prophylactic surgery could impact the morbidity and mortality triggered by these 
mutations. For women with these mutations, surgery could reduce the risk of breast and 
ovarian cancer by 69% (U.S. Preventative Services Task Force, 2014).  
Current USPSTF recommendations are to screen women for a strong family 
history of increased risk for harmful BRCA 1/2 mutations and those identified should be 
offered genetic counseling and potential BRCA 1/2 mutation testing. USPSTF gives this 
recommendation a ‘B’ rating which means that they recommend provision of this service 
because there is a high certainty that the net benefit of this service is moderate and a 
moderate certainty that the net benefit is moderate to substantial (U.S. Preventative 
Services Task Force, 2016). This ‘B’ rating is significant because this allows coverage by 
the Affordable Care Act (Henry J. Kaiser Foundation, 2016). Beyond the USPSTF 
recommendations, some authors propose that population screening for the BRCA 1/2 
mutation would be cost-effective in the high-risk Ashkenazi Jewish population 
(D’Andrea et al., 2016). 
Lynch syndrome (LS). LS, also called hereditary nonpolyposis colorectal cancer 
(HNPCC), is the most common cause of hereditary colon cancer accounting for 3–5% of 
all colorectal cancers (American Cancer Society, 2014; Guillén-Ponce et al., 2012). 
These individuals and their families are also at greater risk for other cancers including 
endometrial, ovarian, and stomach (Guillén-Ponce et al., 2012). LS is an autosomal 





MLH1, MSH2, MSH6, and PMS2, which function to correct mismatched base pairs as 
well as tiny insertions and deletions that occur during DNA replication (Mange et al., 
2015). These corrections are needed to decrease genomic instability which occurs during 
DNA synthesis and mutations in these genes will lead to rapid tumor growth (Guillén-
Ponce et al., 2012). Evidence also shows involvement by an epithelial cell adhesion 
molecule (EPCAM), which indirectly affects DNA repair by causing the MSH2 gene to 
be turned off (Kempers et al., 2011).  
Screening for LS consists of tumor testing by either immunohistochemistry (IHC) 
or microsatellite instability (MSI) followed by genetic sequencing and deletion analysis 
of the MMR genes depending on the results of IHC and MSI (Mange et al., 2015). A 
hallmark of LS is the early-onset of colon cancer diagnosis (< 45 years), so prompt 
identification of patients, tumor testing, and cascade screening of their family members 
could lead to a reduction in LS-caused colorectal cancer incidence and related mortality. 
At this time, evidence supports the integration of Tier 1 condition identification 
and prevention into clinical and public health practice. Tier 1 conditions have been shown 
to have genomic and family health history validation to support inclusion of Tier 1 
genetic testing and screening for susceptible individuals and their family members. Tier 1 
conditions include HBOC, LS, and FH, which are all contributing to the large prevalence 
and burden of cancer and heart disease experienced in the United States today.  
Familial hypercholesterolemia (FH). FH is an autosomal co-dominant disorder 
expressed with abnormally high concentrations of low-density lipoprotein cholesterol 





(CHD) from atherosclerosis (Ned & Sijbrands, 2011). FH is caused by loss-of-function 
mutations in the LDL receptor (LDLR) and apolipoprotein (APOB) genes and gain-of-
function mutations in the proprotein convertase-subtil-sin/kexin type 9 (PCSK9) gene 
(Austin, Hutter, Zimmern, & Humphries, 2004). Untreated, FH poses an approximate 
overall 20-fold increase in CHD from the general population, which includes a 50% CHD 
risk in men by age 50 and a 30% risk of CHD in women by age 60 (Marks, Thorogood, 
Neil, & Humphries, 2016).  
Elevated LDL-C levels in affected individuals begin even before birth and those 
with two abnormal genes (FH homozygotes) can develop CHD very early in life and die 
before age 20 if left untreated (Nordestgaard et al., 2013). FH is as common as Type I 
diabetes, and more common than cystic fibrosis or Down’s syndrome, however, it is 
estimated that only 1-25% of all cases are diagnosed (Knowles et al., 2014; Modell et al., 
2016; Ned & Sijbrands, 2011; Nordestgaard et al., 2013). Identification of individuals at 
risk for FH includes high levels of cholesterol and family and/or personal history of early 
onset CHD. Targeted screening of these individuals for the FH mutation, subsequent 
treatment with lipid lowering pharmaceuticals, and a program of diet and exercise could 
lead to the prevention of tens of thousands of heart attacks over these individual’s 
lifetimes. 
Implementation of Tier 1 Tests: Current Landscape 
In 2002, a Chronic Disease Directors’ Summit was convened to begin the 
dialogue and develop a plan to move genomics out of NBS and into chronic disease units 





CDC to help states respond to the resulting information and applications from the Human 
Genome Project. In 2003, the CDC funded four states, Michigan, Minnesota, Oregon, and 
Utah in 5-year cooperative agreements to integrate genomics into their state public health 
programs (ASTHO, 2010; Green et al., 2015). With annual awards of between $150,000-
$250,000, these states were able to use internal and external planning to integrate FHH 
and genetic testing results into existing genetics and chronic disease policies and 
programs (St Pierre et al., 2014). In addition, they formed partnerships, evaluated public 
data, developed workforce capacity and leadership, and established justifiable 
interventions using FHH, assessments, and educational curricula. After the infrastructure 
was built in the first round, the CDC issued new 3-year cooperative agreements to 
Michigan and Oregon in 2008 in order to shift the focus from capacity building to 
translational activities in public health genomics (ASTHO, 2010). The program focus for 
these agreements was on HBOC surveillance, education, and policy development in 
support of the USPSTF 2005 recommendations.  
In 2011, the OPHG shifted state funding of genomic activities to the Division of 
Cancer Prevention and Control (DCPC) at the CDC to highlight the focus on cancer 
genomics by the Healthy People 2020 objectives. The DCPC granted $300,000 per year 
from 2011–2014 to Michigan, Oregon, and Georgia for HBOC activities and by the end 
of the three-year period, each had an established, effectively operating breast cancer 
genomics program (Trivers et al., 2015). Recently, Utah, Connecticut, and Colorado have 
been included in the support of implementation of evidence-based cancer genomics 





Health Genomics Branch received a Healthy People 2020 Action Award to facilitate 
cancer genomics in that state (Connecticut Department of Public Health, 2012). Other 
states (Ohio, Hawaii, Illinois, and Washington) have fostered state genomic activities 
through implementation grants, academic centers, and collaborations with outside 
stakeholders, but none have been funded to the extent that these model programs have 
(Green et al., 2015).  
Examples of Cancer Genomics Translation by Model States 
The following list describes some ways that model states have integrated cancer 
genomics into their public health programming: 
•   Addition of breast cancer questions to the Behavioral Risk Factor Surveillance 
System (BRFSS). 
•   Analysis of state cancer registry data and using this information to communicate 
and educate providers and patients about potential HBOC counseling and testing 
of patients and their family members. 
•   Development of new surveillance systems with key stakeholders and genetics 
clinics to evaluate uptake of HBOC genetic counseling, testing and follow-up. 
•   Collaboration with public health clinics to integrate HBOC risk screening into the 
clinical intake process. 
•   Analysis of and collaboration with insurance companies to assure coverage for 
genetic counseling and testing for HBOC. 
•   Education of health providers and the public about Tier 1 tests. 





National Resources for State Public Health Genomics 
In 2010, ASTHO developed a State Public Health Genomics Resource Guide 
highlighting the issues, strategies, and challenges to state genomic implementation with 
links to appropriate resources (ASTHO, 2010). This publication also described specific 
activities and tactics that model states were accomplishing to meet clearly defined 
genomic objectives. In 2014, the OPHG published an online Genomic Application 
Toolkit to share the public health genomics methods of these model programs and give 
other states some ideas and advice for development and application of genomic programs 
in their own states (OPHG, 2016a, 2016b). The website explains what the Tier 1 genomic 
applications are, their importance to population health, and how state and local health 
departments can play an important role in the application of Tier 1 tests by identifying 
people who could benefit from testing and extending that benefit to their family 
members. This toolkit also provides links to implementation videos and other resources 
to help. 
The Role of State Chronic Disease Departments in Tier 1 Implementation 
Because the current Tier 1 genetic testing recommendations outside of NBS and 
pharmacogenomics are all identified as hereditary forms of chronic diseases, state and 
territorial CDDs and the personnel who work in these departments should be educated 
about and engaged in Tier 1 genetic testing program implementation (Zimmern & 
Khoury, 2012). Currently, most genomic expertise in state and territorial health 
departments falls within maternal and child health as it relates to NBS issues, however, 





impact of genetics on population health and how to use evidence-based recommendations 
to implement new practices. Unfortunately, many chronic disease programs across the 
country are being reduced, are often underfunded, and are not standardized or as 
comprehensive as they need to be, especially as they relate to genomics (Allen et al., 
2013; Maylahn, Fleming, & Birkhead, 2013). Moreover, it is agreed that a majority of 
public health professionals have not been educated adequately on genomics, whether 
through public health education or on-the-job training (Department of Health and Human 
Services, 2011; Marzuillo et al., 2014). It will be important for CDDs to play a leadership 
role in the integration of genomics into state chronic disease plans, assessment of 
program effectiveness, education of their workforce and the communities they serve, and 
initiation and facilitation of collaborations with stakeholders.  
By 2010, all states had a Comprehensive Cancer Control (CCC) plan in place and 
one study found a significant increase in genomics-related terms in these plans from 
2005-2010 (Laufman et al., 2012). These CCC plans included goals and strategies related 
to FHH, public and provider awareness of genetics and genomics (education), breast 
cancer referrals, access to genetic services, support and expansion of partnerships, 
development and promotion of screening (diabetes), and increased research funding 
(Alzheimer’s disease). The increase in genomic activities could have been in response to 
the Healthy People 2020 goals and/or evidence-based recommendations for cancer 
genomics; however, this study found that genomics still hasn’t grown as a priority at 
most state levels (Laufman et al., 2012). Although evidence-based public health genomic 





commitment for genomics at the state level has been slow due to a shortage of 
organizational leadership and support, lack of understanding, and limited resources for 
competing priorities (Allen et al., 2013) 
Currently there a small number of model states doing work in the area of chronic 
disease public health genomics and most are accomplishing their goals in small 
increments with minimal funding. That being said, the role of state public health 
departments, specifically chronic disease units, in light of the Healthy People 2020 
objectives, Precision Medicine Initiative, and Tier 1 recommendations can and should 
increase to meet these imperatives. Providing evidence of successful programming and 
studying models that work could help obtain funding from sources who may benefit from 
such integration.  
Challenges and Opportunities 
Implementation Barriers 
Since the completion of the Human Genome Project in 2003, the fields of genetics 
and genomics have developed rapidly, yet translation “from bench to bedside” and more 
so from “bench to community” has been a slow process (Cornel, Van El, & Borry, 2014). 
Studies show that the translational process, from research evidence to clinical practice, is 
17 years, however, only 14% of all discoveries actually make it there (Khoury et al., 
2007). Calculating from the date of gene discovery of the Tier 1 tests, FH (1985), LS 
(1987), and HBOC (1995), places the translational timeline to clinical and public health 
application as 2002, 2004, and 2012 respectively (Brown & Goldstein, 1986; Krainer et 





previously, clinical practice guidelines and public health recommendations have been in 
place for some time, yet clinical medicine and public health practitioners are slow to 
adopt suggested practices.  
An expected reason for slow adoption is funding. Ninety-eight percent of genomic 
funding is in the research discovery phase and “bench to bedside” applications while < 
2% is devoted to population translation and outcomes research (Khoury, Gwinn, Bowen, 
& Dotson, 2012; Laurence, 2012). Lack of evidence and data showing health outcomes 
makes it hard to advocate for genomics program funding in the states and outcome data 
from model states is limited. Ironically, governmental support is often based on 
translational research data and translational research cannot be accomplished without 
governmental support (Modell et al., 2014). Moreover, many state chronic disease 
programs have been reduced including a 57% reduction in state funding by the CDC from 
2013–2014 (Allen et al., 2013; Khoury et al., 2011; Maylahn et al., 2013). These limited 
resources along with a lack of organizational support and leadership due to competing 
priorities and an opinion that genomics is a low-yield investment compared to current 
practices will certainly slow or hinder state adoption rates (Allen et al., 2013; Khoury et 
al., 2007). Without strong health data analysis to encourage these evidence-based 
intervention (EBI) applications, it will be difficult to encourage states to move beyond 
their current chronic disease practices.  
Other barriers to genomic translation in state chronic disease departments is the 
lack of awareness and education by public health practitioners, health care providers, and 





model states have included genomics educational assessments and/or programs to 
increase knowledge and awareness about genomics and recommended health practices 
(St Pierre et al., 2014; Trivers et al., 2015). Reimbursement for Tier 1 recommendations 
and other genetic services also limits what states are willing to support (Williams, 2012). 
Cancer genomics is not a mandated public health program like NBS and, without a 
nationalized healthcare system, reimbursement will be dependent on the patient and their 
insurance availability (which may vary widely or depend on the recommendation level) 
(Bowen et al., 2012). Finally, the limitations of our current electronic health records 
system to collect, analyze, and store the large volumes of data could impact health 
outcomes data (Williams, 2012). As this is one of the goals of the Precision Medicine 
Initiative, this data should be easier to ascertain once a better system is in place.   
The Need for Collaboration 
Implementation of public health genomics is difficult and the need for 
collaboration within state public health departments and external stakeholders is the key 
to success (Genetic Alliance, 2014; OPHG, 2011). State public health departments are in 
a unique position to foster these collaborations and mobilize partnerships that will ensure 
a competent public health and clinical medicine workforce as well as assure accessible 
and quality genetic services (Cragun et al., 2016). Because public health departments are 
also the only ones who have the legal authority to collect population data in some 
jurisdictions, they will need to lead the accumulation of this information and tabulate 
health outcome figures (Maylahn et al., 2013). The public health, clinical medicine, and 





patients and susceptible populations have the information about and access to pertinent 
genetic services. Other important external stakeholders reside in hospitals, academic 
centers, local public health organizations, and advocacy organizations (Laufman et al., 
2012). Advocacy organizations are especially important because they help to establish 
buy-in from the public and other organizations (Modell et al., 2016).  
Some states have a state genetics coordinator who’s scope of practice is beyond 
NBS (Coalition of State Genetics Coordinators, 2007). Success in novel public health 
interventions implementation has been tied to strong leadership and champions who are 
passionate about the program (Milat, Bauman, & Redman, 2015). All of the model states 
who have accomplished strides in public health genomics have someone who works part 
or full-time in that capacity at the state level or at an associated academic university. This 
individual can and should be the leader of the coordination, collaboration, and 
communication of state public health genomic services. In addition, collaboration should 
occur between public health agencies at the national, state, and local level as well as 
regional collaboratives to share ideas and challenges (Alexander, Keehn, Kaye, & 
O’Leary, 2016; Bowen et al., 2012). 
Translating genomic advances from the discovery phase to population 
implementation and subsequent improvement in health outcomes is not a small task. 
Many barriers exist including funding, awareness, knowledge, competing priorities, 
reimbursement, and lack of organizational support. In order to overcome these barriers, 
state public health professionals need to collaborate with other stakeholders to assure 





Summary and Conclusions 
With fully validated and clinical practice guidelines for screening of Tier 1 tests 
in place, implementation of screening programs for individuals and their family members 
at risk for HBOC, LS, and FH is ready to be launched through collaborations by public 
health agencies, clinical medicine practitioners, and advocacy groups (Modell et al., 
2016). Because prevention of population morbidity and mortality is a key public health 
endeavor, Tier 1 genetic testing and cascade screening of family members illustrates how 
family health history can be modifiable. State chronic disease departments will be 
instrumental in the delivery of these programs through the formation of strong 
partnerships with many different sectors of the communities they serve.  
CDDs are poised to be the leaders of the dissemination and coordination of these 
new health promotion practices while assuring a focus on the needs of underserved 
populations (American Public Health Association, 2013; Senier et al., 2015). Because of 
this, they will need to understand and help facilitate implementation of Tier 1 genetic 
testing recommendations. Rogers’s diffusion of innovations theory explains that 
communication and influence are impactful to the rate of adoption; encouraging states to 
have an individual who can be the champion for chronic disease genomics would help 
more states adopt this new innovation.  
In Chapter 3, I will outline the methods that were used to perform this study. This 
will include a description of the instrument, participants that were studied, and 





explained through a detailed presentation of the specific variables and statistical tests to 

























Chapter 3: Research Methods 
Introduction  
Following Tier 1 genetic screening and testing recommendations, leaders in state 
and territorial health departments will be called upon to coordinate, collaborate, and 
communicate these initiatives in their areas (Green et al., 2015). This is especially true 
for CDDs, who oversee the areas touched by these recommendations for breast cancer, 
colon cancer, and cardiovascular health. The main purpose of this study was to determine 
whether certain state genomic activities or current genomics funding is associated with 
the level of knowledge and interests in genomics by state and territorial CDDs. This 
could lead to identification of state activities which may help CDDs to be more informed 
and prepared to lead Tier 1 testing and screening in their states. These results may also 
shed light on present knowledge and interests by CDDs providing opportunities and 
insight on challenges for Tier 1 program implementation in the states and a baseline for 
future research. The purpose of this chapter will be for me to describe the research 
questions and hypotheses, survey instrument used, participants, study variables, 
procedures for data collection and coding, and specific data analysis techniques. Finally, I 
will also define potential threats to the validity of the study.  
Research Design and Rationale 
In this quantitative research study, I employed a nonexperimental, cross-sectional, 
correlational survey design to investigate whether there is an association between current 
state funding in genomics and/or specific state genomic activities and the level of 





This study was initiated by a subcommittee of the APHA GFPC, of which I am a 
member, in order to determine the current status of state CDDs in regards to readiness for 
implementation of Tier 1 testing and identify opportunities and challenges to that end. 
The committee agreed that I could perform a secondary analysis of the results of this 
survey to answer the research questions about the possible connection between state 
genomics activities and CDDs knowledge and interests in genomics.  
The survey committee also determined that a quantitative, web-based, self-
administered questionnaire format would be a quick, efficient, and cost-effective design 
to obtain the information sought (see Frankfort-Nachmias & Nachmias, 2008). Using a 
quantitative, cross-sectional survey would allow me to collect important information 
from the study group at a single point in time and delivery via a free web-based service 
that would eliminate costs. The other committee members and I were conducting this 
study voluntarily with no outside funding. Because this is a new instrument developed by 
the GFPC subcommittee members, there was no known reliability or validity at the time 
of this study. Content validity was determined based on the expertise of the committee 
members and other experts in areas which were thought to impact state Tier 1 
implementation. A pilot study of the survey was not performed before delivery to the 
CDDs. 
Quantitative surveys have been used in the past to identify issues in public health 
services delivery (Jacobs, Dodson, Baker, Deshpande, & Brownson, 2010; Stamatakis et 
al., 2012; Wilcox et al., 2014). Survey response rates have also been studied showing that 





impact response rate (Cho et al., 2013; Dillman, 2015; Millar & Dillman, 2011; Pit, 
Hansen, & Ewald, 2013). Moreover, the advent of personal hand-held devices also seems 
to be having a negative impact on the completion of surveys (Stern, Bilgen, & Dillman, 
2014). Because this was a project taken on voluntarily by the GFPC subcommittee (four 
members with no financial support), there was no availability for incentives, mailings, or 
telephone calls. The subcommittee decided to deliver the survey via e-mail link to the 
Internet with a 6-week timeline during which two follow up e-mail requests would be 
made. The benefit of using the Internet includes lower costs, decreased time, and easier 
data entry and analysis (Ahern, 2005). 
The Chronic Disease Directors Survey consisted of 16 dichotomous, Likert scale, 
limited contingency, and demographic questions to determine age, educational degree, 
and state or territory (see Appendix). Some questions included a response of “Don’t 
know” if respondents were unable to accurately answer the question. The first half of the 
survey (nine total questions) contained inquiries about the extent of each state’s activities 
in genomics. The second half of the questionnaire was comprised of questions to gauge 
the participants’ knowledge and interests of genomic topics specifically as they relate to 
chronic disease (four total questions, 18 different topics). Three of these questions were 
based on a Likert scale and were, therefore, used to determine the level of knowledge and 
interests in genomics (1 (very poor) – 5 (very good)) rating of knowledge of Tier 1 
conditions; 1(strongly disagree) – 5(strongly agree) of agreement with genomic 







The selected population for a given methodology is the “aggregate of all cases 
that conform to some designated set of specifications” (Maruyama & Ryan, 2014, p. 
231). For this study, participants were CDDs from all U.S. states, territories (Guam, 
Marshall Islands, Micronesia, Palau, Puerto Rico, Samoa, and U.S. Virgin Islands), and 
the District of Columbia (N = 58). This was a select group with a defined number of 
participants. I was provided with e-mail contact information for the directors and delivery 
of the survey link by the NACDD located in Atlanta, GA (NACDD, 2016b). Founded in 
1988, the NACDD is a nonprofit, public health organization dedicated to supporting 
CDDs in each state and territory by connecting over 6,000 chronic disease practitioners to 
create partnerships, develop policies, implement programs, and share knowledge about 
chronic disease prevention and health promotion (NACDD, 2016a). 
Sampling and Sampling Procedures 
 In this study, I employed a simple random convenience sampling of all CDDs in 
the United States and territories (N = 58), and each director had an equal chance to 
complete the survey. The survey was disseminated to these directors through their 
employee e-mail. I conducted a G*power analysis for the sample size using the t-test 
difference between two dependent means (matched pairs), two tailed, with a medium 
effect size (0.2), 0.05 a, and 0.80 power, which yielded a sample size of 199. As this was 
much greater than the total sample of the population, sample size analysis could not be 





Procedures for Recruitment, Participation, and Data Collection 
In this study, I used data that was originally collected from a quantitative survey 
instrument delivered via the Qualtrics survey platform to the membership of the NACDD 
(N = 58) from February 11, 2016 through March 31, 2016(Qualtrics, 2015). Each 
participant had an equal chance to voluntarily complete the survey with no monetary or 
other compensation provided for doing so. One of the GFPC members provided access to 
the Qualtrics platform through the University of Michigan Medical School Information 
Services with a specific survey link for respondents to connect to the survey 
(https://umichumhs.ut1.qualtrics.com/jfe/form/SV_d6IJGrKYOzZZDb7). The other 
committee members and I obtained access to this dataset from this committee member.  
The CEO of NACDD and the NACDD policy chair were our points of contact in 
the organization, authors of the cover letter, and distributors of the survey link via e-mail. 
The cover letter explained the purpose and importance of the survey to chronic disease 
public health genomics, encouraged participation, and assured confidentiality of 
individual results (see Frankfort-Nachmias & Nachmias, 2008). This method was 
employed for two reminder e-mails (sent on February 25 and March 21, 2016) during the 
survey period. 
Instrumentation and Operationalization of Constructs 
The Qualtrics survey platform allowed for coding of the survey questions within 
the program, automatically assigning a quantitative answer choice value to each selection 
within a question (first answer choice = 1, second choice = 2, etc.). The program also 





measure the variables, I named variables by the question number (Q1, Q2, etc.) and 
identified those with subtopics (e.g. Q9_1, Q9_2, etc.). All of this information was easily 
downloaded into SPSS for analysis. When this survey was originally entered into the 
Qualtrics system, each question was given a number; however, after committee input, 
some questions were relocated on the survey and the numbers were not reordered in the 
Qualtrics system. Therefore, the final survey questions did not follow in numerical order, 
but were identified correctly in SPSS. The Appendix shows the final survey and coding 
scheme that I used.  
In this survey, I assigned the responses for state genomic activities a number (1 = 
Yes, 2 = No, 3 = Don’t know) for all questions except for the frequency of collaborations, 
which was based on a Likert scale (1 = In the past quarter, 2 = In the past year, 3 = 
Rarely, 4 = Never, 5 = Never but potentially in the future). Additionally, question 
subtopics were also coded 1–5 (Q8), 1–7 (Q9), 1–4 (Q13), and 1–9 (Q25) to correspond 
to each subtopic from top to bottom. Except for the question regarding awareness of 
contact information for clinical genetic services (Yes/No), a Likert scaling method was 
used to identify the varying levels of knowledge and interest in genomics by CDDs on a 
5-point continuum (knowledge of Tier 1 conditions rated 1–5 (Q10); agreement with 
genomic statements (Q11) or interest in genomic topics (Q12) rated 1 = Strongly 
disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Strongly agree, 
6=Don’t know (Q11) or 6 = We already do this (Q12). Each Likert scale response was 
given a quantitative number to correspond with the result and this had a direct correlation 





the number, the greater level of knowledge and interest and vice versa. Responses of 
“Don’t know” were identified and removed as outliers during initial statistical analysis 
and then run again to include these results to examine their potential impact.  
The purpose of this study was to determine possible associations between state 
genomic funding as well as specific state genomic activities and the level of knowledge 
and interests in genomics by state and territorial CDDs. Because of this, I considered 
each variable potentially dependent on the other. In other words, no variable was 
considered as an independent or causative variable.  All questions in this survey were 
categorical (nominal); however, Likert scaled questions (Q22, Q23, Q24, and Q25) were 
converted to continuous values (1–5 or 6) for statistical analysis to allow for 
determination of a level of knowledge, interest, or frequency of collaboration by each 
respondent and the study group as a whole; the higher the number, the greater the level of 
knowledge and interest except for levels of collaboration, which employed a reverse 
numbering scheme (see Appendix).  
I considered multiple choice questions with a response of “Yes” (1) present and 
responses of “No” (2) or “Don’t know” (3) were considered absent initially. “Don’t 
know” responses for state activities were changed to (2) to analyze them as not present. 
These results were then returned to their original states to analyze the impact of the 
“Don’t know” responses. Finally, the “Don’t know” response for Q23 (agreement with 
genomic statements) was removed (* in dataset), so it would not be analyzed and impact 





which statistical tests that I used for each association. Finally, I tested data validity and 
reliability with exploratory analysis and Cronbach’s alpha.  
Research Question 1 Variables 
I identified the following variables and subvariables for Research Question 1: 
1.   State funding for chronic disease genomics 
2.   Level of knowledge and interests in genomics by CDDs 
Subvariables: 
2a. Awareness of contact information for clinical genetic services 
      2b. Knowledge of Tier 1 recommended conditions 
      2c. Agreement with genomic statements 
2d. Interest in genomic activities 
Table 5 
Operationalization of Variables for Research Question 1 
Variable pair Question type Variables included 
State genomic funding Categorical 
 
Identified states with funding 
Knowledge and interest Categorical 
Continuous 
2a 
2b, 2c, 2d 
Research Question 2 Variables 
I identified the following variables and subvariables for Research Questions 2: 
1.   State genomic activities. 
            Subvariables: 
            1a. State genetics needs assessment 





            1c. Genetics in state action plan 
            1d. Genetics education 
            1e. Genomics in BRFSS 
            1f. Analysis of state cancer registries 
1g. Genetic legislation 
1h. Frequency of collaborations 
2.   Level of knowledge and interests in genomics by CDDs 
Subvariables: 
 2a. Awareness of contact information for clinical genetic services 
  2b. Knowledge of Tier 1 recommended conditions 
  2c. Agreement with genomic statements 
  2d. Interest in genomic activities 
Table 6 
Operationalization of Variables for Research Question 2 
Variable pairs Question type Variables included 
State genomic activities 
Knowledge and interest 
Categorical 
Categorical 
1-2, 1a-2a, 1b-2a, 1c-2a, 1d-2a, 
1e-2a, 1f-2a, 1g-2a 
State genomic activities 
Knowledge and interest 
Categorical 
Continuous 
1a-2b, 1a-2c, 1b-2b, 1b-2c, 1c-
2b, 1c-2c, 1d-2b, 1d-2c, 1e-2b, 
1e-2c, 1f-2b, 1f-2c, 1g-2b, 1g-2c 
State genomic activities 




State genomic activities 









All survey data were obtained through the Qualtrics survey platform and directly 
exported into IBM SPSS version 23.0 software to perform statistical analysis, which is 
the most appropriate platform for analysis of quantitative survey data (IBM, 2016). The 
raw data was only available to the committee and myself and first examined for and 
cleaned of incomplete or duplicate entries or any other potential abnormalities. Assigned 
variable names and numerical values were also transferred in the statistical report 
downloaded for data analysis. Numerical values for “Don’t know” responses were 
changed to “2” to assure they were not included in the statistical analysis and treated as 
“No” (not present) initially for this study. “Don’t know” values were then returned to 
their original numbers to see what impact, if any, they had on the analysis.  
Descriptive statistics were performed first to identify means, standard deviations, 
and range of values for all variables (Creswell, 2009).  Construction of frequency 
distributions looked at response patterns for all variables with nominal questions showing 
modes and interval questions providing median, mean, range, standard deviation, and 
coefficient of variation (Frankfort-Nachmias & Nachmias, 2008). Frequencies were 
converted into percentages for meaningful interpretation and comparison and visually 
displayed in the results section through tables and graphs. 
Research Question 1 
To what extent, if any, is there an association between states that have received 
funding for chronic disease genomics and the level of knowledge and interests in 





H01: There is no association between states that have received funding for chronic 
disease genomics and the level of knowledge and interests in genomics by state and 
territorial CDDs. 
H11: There is an association between states that have received funding for chronic 
disease genomics and the level of knowledge and interests in genomics by state and 
territorial CDDs. 
 To determine possible associations of the variables in Research Question 1, I used 
Chi-square analysis, the independent t test, and multiple linear regression. Chi-square 
analysis examined possible associations between current state genomic funding and 
whether CDDs knew how to contact genetics professionals if they needed to refer a 
patient or required professional consultation. The independent t test was used to analyze 
whether or not state genomic funding had a possible association with CDDs level of 
knowledge and interest in genomics determined on a continuous scale. Finally, multiple 
linear regression determined possible associations using current state genomic funding as 
the independent variable and the level of knowledge and interest in genomics by CDDs 
(determined on a continuous scale) as the dependent variable. 
Research Question 2 
 To what extent, if any, is there an association between current state genomic 
activities and the level of knowledge and interests in genomics by state and territorial 
CDDs? 
H02: There is no association between any current state genomic activities and the 





H12: There is an association between one or more current state genomic activities 
and the level of knowledge and interests in genomics by state and territorial CDDs. 
Current state genomic activities that were seen as having a potential impact on 
chronic disease public health genomics program implementation were queried. These 
included (a) a state genetics needs assessment, (b) a state genetics needs assessment that 
includes chronic disease conditions, (c) inclusion of genetics in the state public health 
action plan, (d) genetic educational programs, (e) genomics topics on the BRFSS, (f) 
analysis of state cancer registries or other vital records data to identify citizens with 
hereditary cancer syndromes, (g) frequency of collaborations or partnerships with outside 
entities related to genomics, and (h) presence of legislation and/or regulation specifically 
related to genomics. To determine the knowledge and interests in genomics by the CDDs, 
they were asked about their (a) awareness of contact information for clinical genetic 
services for potential referral or consultation, (b) knowledge of Tier 1 recommended 
conditions, (c) agreement with genomic statements, and (d) interest in integration of 
genomic activities.   
The examination of possible associations between the variables for Research 
Question 2 was determined by Chi-square analysis (categorical/categorical), independent 
t test (categorical/continuous), multiple linear regression (continuous/categorical), and 
Pearson’s correlation coefficient (continuous/continuous). Covariation means that “two 
or more phenomena vary together” (Frankfort-Nachmias & Nachmias, 2008, p. 93) and 
this was the basis for the analysis. The null hypothesis will either be rejected or retained 





not show causation of why the two variables are related through cause and effect (Green 
& Salkind, 2011).  
It could be possible to determine whether the association is directional (e.g., an 
increase in state genomic activities will cause an increase in knowledge and interests in 
genomics by CDDs) by selection of a one-tailed test, however, a two-tailed test was used 
to assure detection of an effect in either direction if it exists (Field, 2013). Significance of 
association was determined by a p-value of < .05 and a medium effect size (coefficient of 
determination) was set at 0.20 to examine the amount of variability from the relationship 
of the two variables. Because the sample size was already known in this secondary 
dataset (N = 16), G* Power calculations provide a power (1-b error probability) of 0.116 
with 15 degrees of freedom for this study (see Faul, Erdfelder, Lang, & Buchner, 2007). 
Threats to Validity 
External threats to validity are indicative of the level of generalizability the results 
have to the population being studied (Creswell, 2009). Due to the small number of CDDs 
in the United States and territories (N = 58), it was critical to obtain as many completed 
surveys as possible. Sample size ultimately has an effect on the power of the analysis and 
significance of the results as an indication of the population being studied.  
There can be a variety of reasons why the CDDs did not respond to the survey 
request. Dillman (2015) explains that the age of Internet surveys is similar to the days of 
telephone surveys when individuals were inundated with phone calls seeking information 
to help better understand a group of individuals or population. Today, the volume of 





clean inboxes with only the most crucial information being saved. Completion of surveys 
for someone else’s benefit can be a difficult undertaking especially without an incentive 
(even altruistic) that would encourage participation.  
The most significant error that will likely have an impact on this study will be the 
nonresponse error from those CDDs that do not respond to the survey. Nonresponse can 
also be due to a variety of factors including the type of population, the data retrieval 
method, types of questions, and the number of attempts to get respondents to complete 
the survey (Frankfort-Nachmias & Nachmias, 2008). Because of the significant bias and 
lack of generalizability that can be introduced by nonresponders, it was important to get 
as many responses as possible.  
Because this is a correlational study and does not show causation, internal threats 
to validity are not relevant in this case. Internal threats to validity pertain only to 
experimental studies, which this is not. Moreover, as this is a new study that has never 
been performed before; statistical conclusion validity is unknown at this time.  
Ethical Procedures 
Access to the study population of state and territorial CDDs was facilitated 
through contact with the CEO and policy liaison of the NACDD. Because this study was 
originally performed by the APHA GFPC subcommittee and not connected with any 
organization or university, Institutional Review Board (IRB) approval was not attained 
prior to the original study; it was performed as an exploratory endeavor and not for 
research purposes. IRB approval for secondary analysis of the data for this study was 





are all adult professionals and, therefore, are not considered a part of a vulnerable 
population for study.  
Data for this study were anonymous and had no identifying information that could 
link the results to the participant who answered the survey. There was information 
regarding which states replied, however, this will remain confidential and no information 
regarding individual states' current activities or future plans will be shared. Knowing 
which states participate was only needed to determine the geographic regions represented 
and analyze activities and knowledge and interests from states who have received funding 
against those who have not.  
Once the survey results were downloaded from the Qualtrics system by the 
Genomics Forum Policy subcommittee member who had access, only the other 
subcommittee members had visibility to these results. Data are kept on secure computers 
and will be destroyed after 5 years. Findings will be shared with the NAACD leadership 
and possibly presented in future publications in scholarly journals. 
Summary 
The purpose of this chapter was to outline the specific steps that occurred in order 
to conduct this study of state and territorial CDDs to look at whether current genomic 
funding or certain genomic activities in each state and territory are associated with the 
level of knowledge and interests in genomics by these study participants. This analysis 
looked at each state genomic activity to see if one or more had an impact on the level of 





of knowledge and interests in genomics by CDDs from the states that have received 
funding sought to see if there is an association between these two. 
In Chapter 4, I will describe the research findings and data analysis in detail. The 
chapter will include the data collection procedures, analysis, descriptive statistics, and 
outcomes as they relate to the research questions and theoretical framework. Finally, I 





















Chapter 4: Results 
Introduction 
The purpose of this study was to determine whether there is an association 
between any current state genomic activities or chronic disease genomics funding and the 
level of knowledge and interests in genomics by state and territorial CDDs. In order to 
establish this, I analyzed data from a survey of CDDs using various statistical analyses 
depending on the type of survey question asked to assess possible associations. In this 
chapter, I will report the results of this quantitative survey of CDDs by first describing 
the recruitment, time frame, and response rate for this survey before presenting baseline 
descriptive and demographic statistics of the sample. I will then provide basic univariate 
analysis to show the variables under review. Finally, I will explain the results of the 
statistical analysis performed to answer the research question.  
Data Collection 
Between February 11, and March 31, 2016, all United States and territorial CDDs 
(N = 58) were invited to participate in a voluntary survey regarding genomics. During the 
6-week timeframe for the study, two reminder e-mails were sent to all potential 
participants on February 25 and March 21, 2016. A total of 18 surveys were completed; 
however, two states submitted two separate surveys, so only one from each state was 
selected to be in the study. I based the decision about which survey to use on the 
credentials of the person submitting the survey; the higher credentialed participant was 
presumed to be the chronic disease director. Also, one participant did not answer the 





geolocation platform from the Qualtrics system to determine what state the response 
came from. I used a total of 16 completed surveys for analysis with a response rate of 
27.6%. 
Survey Results 
The study sample of CDDs from state and territorial health departments yielded 
responses from 15 states and one territory and represented all geographic regions of the 
United States except for the South-West South Central Region (see Figure 1). Six (38%) 
of the 16 responses were from states previously identified as innovators and early 
adopters of genomics and that had been provided funding for genomic activities either 
currently or in the past.  The largest majority of CDDs were between 51–60 years of age 
(40%), while 26.7% were in both the 41–50 and 31–40 age range, and one director was 
over 60. All respondents had obtained at least a Master of Public Health or other master’s 
degree with six participants also attaining the level of either MD or PhD. One state did 








Figure 1. Survey representation by region. United States Census Bureau. (2016a).  





Overall, based on these survey results, I found that there were very few states 
actively engaging in genomic activities. Of the total number of questions regarding state 
activities, only 20–30% of respondents’ states engaged in less than half of the actions 
(9/22) considered important in light of Tier 1 genetic testing recommendations. It is also 
worthy to note that most activities currently being conducted relate to breast and colon 
cancer and very few are focused on cardiovascular disease or FH. Furthermore, it appears 
that the same few states are the ones involved in these genomic activities. Figure 2 shows 
the greatest percentage (more than three states) of state activities being performed as 
reported by the CDDs.  
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Table 7 describes frequencies and percentages of state genomic activities as reported 
“Yes” by the survey respondents. 
Table 7    
State Genomics Activities    
Activity Frequency (N) Percentage (%) 
Conducted genetic needs assessment 1 6 
Genetic needs assessment includes action 
around chronic disease 
1 6 
Genetics in state action plan for:   
Chronic disease 2 12 
Cancer control 4 25 
Cardiovascular health 2 12 
Genetic education integrated in:   
Breast cancer 5 31 
Colorectal cancer 4 25 
Ovarian cancer 4 25 
Cardiovascular disease 1 6 
Questions on BRFSS   
Breast/cervical cancer screening 3 19 
Colorectal cancer screening 3 19 
Health care access 1 6 
Cancer registry analysis 3 19 
Legislation/regulations   
Nondiscrimination laws 5 31 
Privacy rules 4 25 
Informed consent 1 6 
Provision of genetic services to uninsured 
and low income individuals 
1 6 







Frequency of Collaborations 
In the survey, CDDs were asked how often they engaged in collaborations or 
partnerships in relation to genomics with groups outside of the state health department. 
Only 20–30% of CDDs are collaborating with any regularity and it appears that the same 
4–5 CDDs have been collaborating across the board. Table 8 illustrates the frequency of 
collaborations and partnerships occurring with each of these entities. 
Table 8 
Frequency of Collaborations or Partnerships Related to Genomics with Outside Entities 
 
In the past 
quarter 
 In the 
past year Rarely Never 
Never but 
potentially 
in the future 
 
       
N % 
      
N %      N %      N    %       N % 
Academic 
institutions 
       
5 31       1 6     4 25      3 19       3 19 
Primary care 
providers 
       
5 31       1 6      7 44       1 6 
Genetic 
counselors 
       
4 25 
       
1 6      3 19      6 38       2 13 
Other clinicians        
4 25 
       
1 6       3 19      5 31       1 6 
Advocacy 
groups 
       
4 25         2 13      6 38       1 6 
Hospitals and 
healthcare 
systems 3 19 1 6       2 13      7 44       2 13 
Third party 




       
1 6 
       






Knowledge and Interest in Genomics by CDDs 
Knowledge of genetics professionals.  CDDs were asked if they knew how to 
contact genetics professionals in their state/territory if they needed genetic expertise 
consultation or patient referral for genetic services. Sixty-three percent acknowledged 
that they would be able to contact genetics professionals if the situation presented itself; 
the other 37% said they did not. This question did not include a response of “Don’t 
know.” 
Knowledge of Tier 1 conditions. CDDs were asked to rate their level of 
knowledge of the recommended Tier 1 conditions: HBOC, LS, and FH. The rating scale 
was from 1 = very poor to 5 = very good. Knowledge was greatest in HBOC (M = 3.13, 
SD = 1.46), and “somewhat poor” for FH (M = 2.50, SD = 1.27) and LS (M = 2.13, SD = 
1.20). 
Agreement with genomic statements. CDDs were given six different genomic 
statements and asked about their level of agreement with each one. Responses ranged 
from 1 (strongly disagree) to 5 (strongly agree). A value of 6 (Don’t know) was also an 
option; however, these results were removed when calculating the mean values to avoid 











Agreement with Genomic Statements Regarding Importance of Genomics 
To what extent do you agree or disagree with the 
following statements? N M Range SD 
Genetic counseling and testing for hereditary cancer 
conditions can improve a patient's health outcomes 16 4.00 3–5 0.73 
Integrating genetics into public health planning for 
chronic disease programming would benefit residents of 
our state. 16 3.88 1–5 1.09 
Genetics is an important component of public health 
initiatives 15 3.73 3–5 0.80 
Legal protections against genetic discrimination are 
adequate in our state. 8 3.13 2–4 0.64 
As a whole, staff in the Chronic Disease Program 
understands how genetics relates to chronic disease 15 2.87 1–4 1.19 
Citizens in our state understand how family history or 
genetics influences risk of chronic disease 15 2.67 1–4 1.18 
          Note. Results greater than 3.00 were considered positive agreement. Results of 6 (Don’t    
          know) were removed to avoid skew. 
Level of interest in genomic activities. Providers were questioned on nine 
activities considered important to genomics integration and asked how strongly they 
agreed or disagreed with their existence. Responses ranged from 1 = strongly disagree to 
5 = strongly agree. An option of 6 (We already do this) was included in mean value 
calculation as it supports agreement of the importance of an activity. Table 10 provides 








Level of Interest in Incorporating Genomic Activities 
In my role as a CDD, I would be 
interested in: N M Range SD 
Incorporating genomics into our 
comprehensive action plan 15 4.33 2–6 1.23 
Incorporating genomics into other 
cancer policies and initiatives 15 4.20 1–6 1.37 
Utilizing Cancer Registry data to 
identify high risk patients with the 
goal of reducing morbidity and 
mortality 15 3.93 3–5 0.70 
Promoting or enhancing genomics 
awareness among medical providers 15 3.93 3–5 0.70 
Incorporating cancer genomics into 
our state's Breast and Cervical Early 
Detection Program 14 3.86 2–5 0.95 
Promoting or enhancing genomics 
awareness among the general public 15 3.73 1–5 0.96 
Finding funding to hire an individual 
to focus on genomics and chronic 
disease programming 15 3.53 1–5 1.25 
Incorporating ID of 
individuals/cascade screening for FH 
into Cardiac Disease Prevention 
Program 15 3.40 1–5 0.91 
Recommending the addition of 
genomics questions to the BRFSS 
cancer modules 15 3.33 1–5 1.11 
Note. Results greater than 3.00 were considered a positive interest. Results included a 







Data Analysis Results 
I performed statistical analysis to determine possible associations on all variables 
provided through the survey results as well as evidence of state genomic funding. Chi-
square, t test, ANOVA, multiple regression, and Pearson’s correlation were used 
depending on the type of variables examined. I also performed analysis in duplicate, once 
with the “Don’t know” responses included and again after changing these results to “No.” 
This was to acknowledge the “Don’t know” responses as possible presence of an activity 
and then to recognize that the “Don’t know” responses could mean the activity did not 
exist. 
Research Question 1 
Research Question 1: To what extent, if any, is there an association between states 
that have received funding for chronic disease genomics and the level of knowledge and 
interests in genomics by state and territorial CDDs ? 
H01: There is no association between states that have received funding for chronic 
disease genomics and the level of knowledge and interests in genomics by state and 
territorial CDDs. 
H11: There is an association between states that have received funding for chronic 
disease genomics and the level of knowledge and interests in genomics by state and 
territorial CDDs. 
Chi-Square 
Part of Research Question 1 was analyzed using Chi-square analysis to determine 





interests in genomics by the directors. An assumption of the Chi-square test is that all 
results are independent of one another and will only provide one piece of data to one cell 
of the contingency table; no data will be used repeatedly (Field, 2013). Moreover, 
expected frequencies should be no lower than 5, which could be troublesome with a small 
sample size, and could have a large impact on test power. 
This analysis specifically looked at whether or not a state had been identified as a 
funded state and if the CDD knew how to refer patients for genomic services or find 
expert genomic consultation in their state (Q16). Chi-square analysis showed no 
association with these variables (X2(1)=.071, p=.790, phi=.067; Likelihood ratio 
X2(1)=.072, p=.789, phi=.067). These results, therefore, accept the null hypothesis for 
Research Question 1 and indicate there is no association between these variables. 
Independent t test 
Part of Research Question 1 was also analyzed by the independent t test to see if 
funding was associated with CDDs’ level of knowledge about Tier 1 conditions, interest 
in genomic topics, and agreement with genomic statements (Q22_1–3, Q23_1–6, Q24_1–
9). The independent t test is a parametric test that assumes normality of the sampling 
distribution, outcome variables are related linearly to predictor variables, and the samples 
will come from a population with the same variance regardless of the level of predictor 
variable (Field, 2013). The final assumption is that the samples are all independent of one 
another. This analysis again accepted the null hypothesis for Research Question 1 and 







Presence of State Genomic Funding vs. Knowledge or Interest of Genomic Topics 
Knowledge or Interest t p value 95% CI 
HBOC t(14) = 1.17 .263 -.726 – 2.46 
LS t(14) = 2.00 .066 -.085-2.35 
FH t(14) = .807 .433 -.884-1.95 
Citizens understand 
genomics and chronic 
disease 
t(11) = -.693* .502 -1.67 - .865 
Staff understands 
genomics and chronic 
disease 
t(13) = -.519 .613 -1.72 – 1.06 
Genetic counseling 
improves outcomes 
t(14) = .695 .499 -.557 – 1.09 
Integrating genetics 
benefits state residents 
t(14) = .822 .425 -.751 – 1.69 
Legal protections are 
adequate 
t(6) = -.685 .519 -1.53 - .858 
Genetics is very 
important to public 
health 
t(13) = .221 .829 -.879 – 1.08 
Add BRFSS genomics 
to cancer modules 
t(13) = .158 .877 -1.27 – 1.47 
Use of cancer registry to 
ID at-risk individuals 
t(13) = 1.04 .317 -.430 – 1.23 
Incorporating genomics 
into cancer action plan 
t(13) = 1.04 .318 -.757 – 2.16 
Incorporating genomics 
in other cx policies 
t(13) = 1.22 .245 -.698 – 2.50 
Incorporating genomics 
into breast/cervical 
cancer early detection 
t(12) = .406 .692 -.970 – 1.42 
Incorporating ID of FH 
in cardiac screen 
t(13) = .587 .567 -.803 – 1.40 
Promote public 
awareness 
t(13) = .183 .857 -1.08 – 1.28 





Knowledge or Interest t p value 95% CI 
Promote provider 
awareness 
t(13) = .251 .806 .762 - .962 
Funding state genetics 
coordinator position 
t(13) = .572 .577 -1.11 – 1.91 
Note. CI = Confidence Interval. Negative t values suggests the sample mean was below 
the hypothesized mean (see Field, 2013). 
*Levine’s statistic was significant; therefore, t statistic is from variances not assumed. 
 
Multiple Linear Regression  
Finally, part of research question one was also analyzed by multiple linear 
regression to examine the “flip” of the independent t test. This analysis looked at funding 
as the independent, categorical variable, and knowledge and interest in genomics by the 
CDDs as the dependent, continuous variable (Q22_1–3, Q23_1–6, Q24_1–9). The linear 
model assumes that the outcome variable is linearly related to the predictor variable, the 
samples have a constant variance, and are normally distributed (Field, 2013). Predictors 
should also be independent and uncorrelated to any external variables or linear to another 
predictor. This analysis provided a single association, rejecting the null hypothesis for 
Research Question 1, with funding and CDDs agreement with the statement “Citizens in 
our state understand how family history or genetics influences risk of chronic disease” 
F(1,13) = 16.20, p = .028. 
Research Question 2 
Research Question 2: To what extent, if any, is there an association between 
current state genomic activities and the level of knowledge and interests in genomics by 





H02: There is no association between any current state genomic activities and the 
level of knowledge and interests in genomics by state and territorial CDDs. 
H12: There is an association between one or more current state genomic activities 
and the level of knowledge and interests in genomics by state and territorial CDDs. 
Chi-Square 
This analysis and looked at possible associations between state genomic activities 
and knowledge and interest in genomics by CDDs. Specifically, this analysis looked at 
presence or absence of state genomic activities (Q11, 29, 13_1–4. 8_1–5, 9_1–7, 10, 
15_1–5) and whether the chronic disease director knew how to refer patients for genomic 
services or find expert genomic consultation in their state (Q16).  The first analysis 
included the “Don’t know” results and identified seven state genomic activities that were 
associated with referral and consultation knowledge by the CDDs. Table 12 depicts the 
results that reject the null hypothesis for Research Question 2 and are significant 
associations. Note that only two activities had a significant Pearson Chi-square and all 
other results were based on the Likelihood ratio, which is an alternative to Pearson’s 
(Field, 2013). Also, one of the significant Pearson results (Education – Other) only had a 











Presence of State Activity vs. Knowledge of Genomic Referrals or Consultations- 
“Don’t Know” Included 
SGA Pearson’s Chi square Likelihood ratio 
Action plan - 
cancer control 
 X2(2, N = 16) = 7.71, p = .021, 
phi = .60 
Action plan - 
other 
 X2(1, N = 14) = 4.39, p = .036, 
phi = - 47 
Education - 
breast cancer 
 X2(2, N = 16) = 6.26, p = .044,  
phi = .54 
Education - 
other 
X2(1, N = 4) = 4.00, p = .046,  
phi = -1.00 
X2(1, N = 4) = 5.55, p = .019, 
phi = -1.00 
Regulations - 
discrimination 
X2(1, N = 16) = 4.36, p = 
.037, phi = .52 
X2(1, N = 16) = 6.01, p = .014,  
phi = .52 
Regulations - 
privacy 
 X2(1, N = 16) = 4.53, p = .033, 
 phi = .45 
Regulations - 
genetic services 
 X2(2, N = 16) = 7.71, p = .021, 
phi = .62 
    Note. SGA = State genomic activity 
Table 13 provides results of the same analysis; however, the “Don’t Know’ 
results were changed to “No” in the data set. This analysis provided six different 
associations including two Pearson Chi-square results. The following state genomic 
activities were found signficantly associated with knowledge of genomic referral or 











Presence of State Activity vs. Knowledge of Genomic Referrals or Consultations 
“Don’t Know” Changed to “No” 
SGA Pearson’s Chi square Likelihood ratio 
Action plan - 
cancer control 
 X2(1, N = 16) = 4.53, p =.033, 
phi = .45 
Education – 
breast cancer 
X2(1, N = 16) = 4.36, p = .037, 
phi = .52 
X2(1, N = 16) = 6.01, p = .014, 




 X2(1, N = 16) = 4.53, p = .033, 
phi = .45 
Education – 
ovarian cancer 
 X2(1, N = 15) = 5.03, p = .025, 
phi = .49 
Regulations - 
discrimination 
X2(1, N = 16) = 4.36, p = .037, 
phi = .52 
X2(1, N = 16) = 6.01, p = .014, 
phi = .52 
Regulations - 
privacy 
 X2(1, N = 16) = 4.53, p = .033, 
phi = .45 
   Note. SGA = State genomic activity 
Independent t test 
The independent t test was used to identify a possible association between the 
presence or absence of state genomic activities (Q11, 29, 13_1–4. 8_1-5, 9_1–7, 10, 
15_1–5) and the level of chronic disease director knowledge of Tier 1 conditions, interest 
in genomic topics, and agreement with genomic statements (Q22_1–3, Q23_1–6, Q24_1–
9). This test was also used to study potential associations between frequency of genomic 
collaborations (Q25_1–9) and whether the CDD knew how to refer patients for genomic 
services or find expert genomic consultation in their state (Q16). Tables 14 and 15 
represent the significant associations that reject the null hypothesis for Research Question 
2. Note that some results had a statistically significant Levine’s statistic, which means 





and the t value was negative suggesting that the sample mean is below the hypothesized 
mean (Field, 2013). 
Table 14 
Frequency of Genomic Collaborations vs. Knowledge of Genomic Referrals or 
Consultations 
Collaborations t p value 95% CI 
Primary care providers t(10) = -3.71* .004 -3.16 - -0.80 
Other clinicians t(12) = -3.31* .006 -2.95 - -0.61 
Advocacy groups t(9) = -3.68* .005 -3.15 - -.075 
Hospital/ health systems t(12) = -2.76* .018 -2.51 - -0.29 
Third party payers t(11) = -3.83* .003 -2.76 - -0.75 
Note. CI = Confidence Interval. All t values were negative and suggests the sample mean 
was below the hypothesized mean (Field, 2013). 
*Levine’s statistic was significant; therefore, t statistic is from variances not assumed. 
 
Table 15     
State Genomic Activities vs. Level of Knowledge or Interest of Genomic Topics “Don’t 
Know” Changed to “No” 
SGA Knowledge or interest t p value 95% CI 
Action plan –  
cardiovascular 
health 
LS t(13) =  = 7.81* .000 1.55-2.74 
 FH t(13) = 5.33* .000 1.02-2.41 
 Staff understands 
genomics and chronic 
disease 
t(12) = 3.90* .002 0.59-2.02 
 Legal protections are 
adequate 
t(6) = -2.47 .049 -2.56- -.009 
Education –  
breast cancer 
LS t(14) = 2.97 .010 0.43-2.69 





SGA Knowledge or interest t p value 95% CI 
Education – 
colorectal cancer 
LS t(14) = 3.48 .004 0.70-2.96 
Education –  
ovarian 
LS t(13) = 2.38 .033 0.13-2.61 
Education –  
cardiovascular 
disease 
Legal protections are 
adequate 
t(6) = - 2.47** .049 -2.56 --.009 
BRFSS questions–  
health care access 
Legal protections are 
adequate 
t(6) = - 2.47** .049 -2.56 --.009 
Regulations –  
privacy 
LS t14) = 2.51 .025 0.22-2.78 
 Interest in FH screen t(13) = 2.26 .042 .050-2.28 
 Promoting provider 
awareness 
t(13) = 2.31 .038 .059-1.78 
Note. CI = Confidence Interval. Negative t values suggest the sample mean was below 
the hypothesized mean (see Field, 2013) SGA = State genomic activity. 
 *Levine’s statistic was significant; therefore, t statistic is from variances not assumed. 
** No Levine statistic was provided.  
 
ANOVA 
Analysis of variance was used to analyze the same previous set of data (presence 
or absence of state genomic activities (Q11, 29, 13_1–4. 8_1–5, 9_1–7, 10, 15_1–5) and 
the level of chronic disease director knowledge of Tier 1 conditions, interest in genomic 
topics, and agreement with genomic statements (Q22_1–3, Q23_1–6, Q24_1–9) only 
with inclusion of the “Don’t know” responses. ANOVA was required to analyze this 
association because the factor (state genomic activity) is now in three groups. The one-
way ANOVA is performed with three assumptions; the dependent variable is normally 
distributed, the population from which the dependent variable samples come from have 





(Green & Salkind, 2011). Table 16 provides the results of this analysis and significant 
associations that reject the null hypothesis for Research Question 2. 
Table 16 
State Genomic Activities vs. Level of Knowledge or Interest of Genomic Topics “Don’t 
Know” Included 




in BRFSS cancer 
modules 
F(1,13) = 16.26 .001 
 Incorporating genomics 
into cancer policies 
F(1,12) = 4.82 .048 
 Promoting public 
awareness 





in BRFSS cancer 
modules 
F(1,11) = 5.58 .038 
Action plan –  
cardiovascular 
health 
LS F(2,13) = 3.85 .049 
Education –  
breast cancer 
LS F(2,13) = 5.97 .015 
 FH F(2,13) = 13.33 .001 
 Interest in FH screen F(2,12) = 5.06 .025 
Education –  
colorectal cancer 
LS F(2,13) = 12.61 .001 
 FH  F(2,13) = 4.33 .036 
 Interest in FH screen F(2,12) = 4.71 .031 
Education –  
ovarian cancer 
LS F(2,12) = 7.50 .008 





Legal protections are 
adequate 
F(2,13) = 4.66 .030 





SGA Knowledge or interest F p value 
 Genetics is very 
important in public 
health 





Genetics is VIP in PH F(1,14) = 7.21 .018 
BRFSS 
questions –  
colorectal cancer 
Legal protections are 
adequate 





Genetics is very 
important in public 
health 




Genetics is very 
important in public 
health 





Genetics is very 
important in public 
health 
F(1,14) = 7.21 .018 
Use of cancer 
registry 
Legal protections are 
adequate 
F(2,13) = 4.01 .044 
Regulations –  
privacy 
LS F(1,14) = 6.30 .025 
 Legal protections are 
adequate 
F(1,14) = 7.96 .014 
 Interest in FH screen F(1,13) = 5.07 .042 
 Promoting provider 
awareness 
F(1,13) = 5.33 .038 




Funding state genetics 
coordinator position 
F(1,13) = 5.43 .037 
Regulations –  




F(2,12) = 6.24 .014 
 Funding state genetics 
coordinator position 
F(2,12) = 4.03 .046 





Multiple Linear Regression 
Multiple linear regression was used to analyze continuous and categorical 
variables from the survey much like the independent t-test for possible associations 
between categorical state genomic activities (Q11, 29, 13_1–4. 8_1–5, 9_1–7, 10, 15_1–
5) and the level of chronic disease director knowledge of Tier 1 conditions, interest in 
genomic topics, and agreement with genomic statements (Q22_1–3, Q23_1–6, Q24_1–9). 
Responses of “Don’t know” were included. This analysis resulted in no associations and 
accept the null hypothesis for Research Question 2. 
This analysis was also used to identify potential associations of frequency of 
genomic collaborations and CDD knowledge of genomic referrals and consultations. This 
again, was a reverse analysis of the independent t-test performed earlier. This analysis 
found one association with primary care providers F(1,15) = 7.71, p = .039; the multiple 
correlation coefficient was 0.78. This was the only significant association to reject the 
null hypothesis for Research Question 2. 
Pearson’s Correlation Coefficient 
The Pearson’s correlation coefficient was used to analyze possible associations 
with survey questions that were both continuous (State genomic activity – Q25 – 
frequency of collaborations; KI - Q22_1–3, Q23_1–6, Q24_1–9 - level of CDD 
knowledge of Tier 1 conditions, interest in genomic topics, and agreement with genomic 
statements). Only collaborations in the past quarter or past year were included as they 
suggest more frequent partnerships. Pearson’s r is significant if the two variables are 





normally distributed while ignoring the other variable and is normally distributed at all 
levels of the other variable. Another assumption is that all variables are sampled 
randomly and independent of one another. Table 17 presents all signifcant results from 
the Pearson correlation coefficient analysis that reject the null hypothesis for Research 
Question 2. 
Table 17 
Frequency of Collaborations vs. Level of Knowledge or Interest of Genomic Topics  
Collaboration Knowledge or Interest r p value 
Academic 
institutions 
HBOC r(14) =.59 0.016 
 LS r(14) =.54 0.031 
 Genomics into comprehensive 
cancer plan 
r(13) =.55 0.034 
 Genomics into other cancer 
policies 
r(13) =.56 0.030 
Primary care 
providers 
LS r(12) = .73 0.003 
 FH r(12) = .59 0.026 
 ID of FH individuals and family 
members 
r(11) = .57 0.044 
Genetic 
counselors 
HBOC r(14) = .54 0.32 
Other clinicians LS r(12) = .73 0.003 
 FH r(12) = .58 0.029 
 Using cancer registry data  r(11) = .57 0.042 




LS r(13) = .69 0.021 
 Using cancer registry data  r(12) = .56 0.038 
Third party 
payers 
LS r(12) = .58 0.031 
Local and county 
health 
departments 
Interested in promoting or 
enhancing genomic awareness 
among medical providers 
r(12) = .59 0.027 






Analysis of data for Research Question 1, which looked at the possible 
association of current state genomic funding and the level of knowledge and interest in 
genomics by CDDs showed only one association; CDDs agreement with the statement 
“Citizens in our state understand how family history or genetics influences risk of chronic 
disease.” This single association demonstrates that current state genomic funding has 
very little impact on the level of knowledge and interest in genomics by CDDs. 
Analysis of associations for Research Question 2 however, presence of state 
genomics activities and level of knowledge and interests in genomics by CDDs, showed 
many significant associations. Existence of cancer control action plans, breast, ovarian, 
and colorectal education, and regulations pertaining to non-discrimination and privacy 
were significantly associated with CDDs knowledge of genomic referrals for patients or 
consultation for themselves. These associations were intact whether “Don’t know” 
responses were included or not. 
ANOVA and independent t test results found that breast, ovarian, and colorectal 
education is associated with CDD’s knowledge of LS, FH, interest in incorporating 
identification of individuals/cascade screening for FH in the state Cardiac Disease 
Prevention Program, and agreement that legal protections against genetic discrimination 
are adequate in their states. Questions related to the presence of genomic topics on the 
BRFSS were associated with CDDs agreement that genetics is an important component 
of public health initiatives and that legal protections against genetic discrimination are 





interest in recommending the addition of genomics questions to the BRFSS cancer 
modules, incorporating genomics into other cancer polices and initiatives, and promoting 
or enhancing genomics awareness among the general public. Having a state action plan in 
cardiovascular health was associated with knowledge of LS and FH and agreement that 
legal protections against genetic discrimination are adequate in their states. Finally, 
current state regulations for genetic privacy, providing genetic services to uninsured or 
low income residents, and funding a state genetics coordinator position were associated 
with CDD’s agreement that legal protections against genetic discrimination are adequate 
in their states, and interest in incorporating identification of individuals/cascade screening 
for FH in the state Cardiac Disease Prevention Program, promoting or enhancing 
genomics awareness among medical providers,  as well as funding for a state genetics 
coordinator position. 
Pearson’s correlation discovered that CDD knowledge of Tier 1 conditions was 
associated with more frequent collaborations with academic institutions (HBOC, LS), 
other clinicians (LS, FH), genetic counselors (HBOC), and primary care providers, 
advocacy groups, hospitals and healthcare systems, and third party payers (LS). CDDs 
were more interested in incorporating genomics into the comprehensive cancer action 
plan and other cancer policies and initiatives when they collaborated frequently with 
academic institutions and would be more likely to want to incorporate the use of the state 
cancer registry to identify high risk patients if they collaborated with other clinicians or 
hospitals and healthcare systems. Lastly, CDDs would be interested in incorporating 





Prevention Program if they collaborated with primary care providers and were interested 
in promoting or enhancing genomic awareness among medical providers if they 
connected with local and county health departments. 
In this results chapter, I provided specifics about the data collection used in this 
study, results of the statistical analysis, and a summary of the findings of the survey of 
state and territorial CDDs. These findings showed a number of significant associations 
with specific state genomic activies and the level of knowledge and interest in genomics 
by state and territorial CDDs. In the final chapter of this dissertation, I will provide an 
interpretation of the findings, limitations of the study, recommendations for further 

















Chapter 5: Discussion, Conclusions and Recommendations 
Introduction 
Given the potential that genomic technologies have for identifying individuals and 
their families at risk of heritable chronic disease and targeting public health prevention 
efforts, I have been puzzled at the slow uptake of these interventions. As state public 
health organizations are essential in the national effort to promote the use of genomic 
information to reduce morbidity and mortality and save lives (Green et al., 2015), 
examining what might be impacting this slow integration could shed light on future steps. 
In order to do this, I performed a secondary analysis of a survey of state and territorial 
CDDs about current state genomic activities and their level of knowledge and interest in 
genomic topics believing CDD’s familiarity with genomics could impact their leadership 
in this area. To date, only a small number of states have received funding to incorporate 
genomics into their chronic disease programming, so one purpose of this study was to see 
if this funding was associated with an increased level of knowledge and interest in 
genomics by CDDs. The second purpose of this study was to examine if any current state 
genomic activities were linked to the level of knowledge and interest in genomics by 
these CDDs. 
Based on the results of this survey, it appears that state chronic disease genomics 
funding has almost no impact on the level of knowledge and interest in genomics by the 
CDDs. There were, however, many significant associations with respect to specific state 
genomic activities and CDDs’ knowledge and interest. State activities that were 





genomics needs assessment (n = 1); genetics inclusion in cancer control and 
cardiovascular health action plans; breast, ovarian, and colorectal cancer genetics 
education; and state laws or regulations pertaining to genetic nondiscrimination, privacy, 
providing genetic services to uninsured or low-income residents, and funding a state 
genetics coordinator position. Inclusion of genomics on BRFSS topics related to 
breast/cervical cancer screening, cardiovascular health, colorectal cancer, genetic 
discrimination, and privacy were also associated with a higher level of knowledge and 
interest in genomics by the CDDs. Finally, frequent collaborations (in the past 
quarter/year) with outside entities, mainly academic institutions, primary care providers, 
and other clinicians were associated with greater levels of knowledge and interest, 
especially for knowledge of Tier 1 conditions and particularly LS. 
Interpretation of Findings 
The framework from the literature on Rogers’ diffusion of innovations theory 
indicated that disseminating, implementing, and sustaining new innovations depends 
largely on sufficient knowledge of the innovation to progress through the phases of 
adoption (Rogers, 2003). According to this theory, individuals’ knowledge can impact 
their attitudes which, in turn, influence their decision to adopt and implement an 
innovation. Rogers also explained that those who adopt later in the process will require a 
longer innovation-decision period. This is particularly important as more states adopt 
chronic disease genomics programming. Therefore, pinpointing associations between 





identify actions that might be associated with this desired outcome, chronic disease 
genomics implementation. 
However, initially in this study I examined the potential association of state 
genomic funding and the level of knowledge and interest in genomics by the CDDs. An 
individual would imagine that states with chronic disease genomics funding would have 
more state activities and CDDs with a greater interest in genomic integration. Six (38%) 
of the 16 surveys received were from states identified as funded for chronic disease 
genomic activities; however, statistical analysis did not show a significant association 
with funding and the level of knowledge and interest in genomics by the CDDs of those 
states. As I was looking at an association and could not show causality in this study, one 
conclusion that can be made is that the greater knowledge and interest in genomics was 
driven by the CDD(s) themselves and was not related in any way to the funding provided 
to individual states. There were, in fact, some states that did not receive funding and had 
little or no state genomic activities, yet the CDDs were more knowledgeable and 
interested than others.  
This also leads into the prior described theory that the genomics champion in the 
funded states is influential in integrating genomics into state chronic disease programs 
(Schon, 1963; Taylor et al., 2011). Rogers (2003) is clear that this champion is 
instrumental to the success of an innovation and has a positive impact on the rate of 
adoption. As these funded states often have at least one person, the champion, seeking 
this funding, driving the work, and producing evaluative data, this model seems like it 





Because the statistical analysis showed no association, a possible conclusion is that those 
CDDs with increased knowledge and interest in genomics could, themselves, become that 
genomics champion that is integral to adoption of this innovation in their states.  
In this study, I identified that there are, in fact, specific state genomic activities 
that are associated with greater knowledge and interest in genomics by state and 
territorial CDDs. Educational programs related to the Tier 1 conditions were associated 
with greater knowledge and interests by the CDDs; however, this was only for LS and 
FH. Interestingly, HBOC was not associated with increased knowledge and interest in 
HBOC. This mismatch is likely due to the small sample size; however, using educational 
endeavors to increase knowledge in genomics is not a new concept (Khoury, Gwinn, 
Dotson, & Schully, 2012; Talwar, Tseng, Foster, Xu, & Chen, 2016). 
The BRFSS is used to survey U.S. residents concerning health-related risk 
behaviors, chronic diseases, and prevention measure utilization (CDC, 2017). Responses 
to questions on the BRFSS are used by CDDs and others as one of the indicators of state 
and selected metropolitan-level chronic diseases and risk factors that impact public health 
(Holt et al., 2015). This system is not only used for surveillance but for prioritizing and 
evaluating public health interventions. The fact that BRFSS genomics-related questions 
were found to be significantly associated with greater knowledge and interest in 
genomics by the CDDs is, therefore, potentially meaningful if CDDs translate that 
interest into leadership to prioritizing genomics into chronic disease programming.  
One of the six components of successful public health program implementation 





(Frieden, 2014). In this study, I found that CDDs who collaborated with academic 
institutions and medical professionals significantly increased their knowledge and interest 
in genomics. Academic institutions are often where genetics professionals (geneticists, 
genetic counselors) and researchers are based and these individuals can provide a wealth 
of knowledge in this area. The fact that collaborations with genetic counselors was not 
determined to be a significant factor in increased knowledge and interest could be 
because of the limited number of these professional nationwide (Wicklund & Trepanier, 
2014).  
Using Rogers’ Theory to Diffuse Chronic Disease Genomics in More States 
Although prevention is usually cheaper than treatments, new prevention efforts in 
public health frequently diffuse slowly due to the delay in observance of clear health  
outcomes and perception of the relative advantage by public health leadership (Rogers 
2002). One factor impacting the rate of adoption is the complexity, or perceived difficulty 
of and innovation among members of a social system. Increasing the knowledge and  
interest in chronic disease genomics by CDDs will impact their perception of the 
complexity of these applications and help them gain a greater understanding of the  
potential health impact to their populations. In this study, I have identified specific 
genomics activities currently being performed by states that are having an impact on this 
knowledge and interest by CDDs. When trying to identify ways to diffuse chronic disease 
genomics in more states, these activities would be the ones to start with. 
Rogers (2002) also mentions the importance of the early adopters to the diffusion 





diffusion of chronic disease genomics, the early majority, will be looking towards these 
states for modelling, information, and advice. Based on the current landscape, I had 
previously identified seven early adopter states; however, results of this survey show that 
there are other states that are already doing work in this area and could also be 
instrumental opinion leaders and models on how to do this work without funding specific 
to chronic disease genomics.  
Limitations of the Study 
As I previously described in the Introduction, one of the limitations of this study 
was the small sample size of the study group and subsequent limited number of CDDs (N 
= 16) who responded to the survey. The total response correlates to published survey 
response rates; however, had the APHA GFPC subcommittee decided to extend the 
survey timeframe to longer than 6 weeks or sought alternative follow-up contact (such as 
phone calls or mailings), this may or may not have had an impact on the number of final 
responses received. I cannot know whether a delivery of this survey at an alternate time 
or under different circumstances would impact the survey response rate. It is known that 
limited datasets can impact study power and external validity (generalizability; Field, 
2013); nevertheless, my analysis was able to find significant associations that can be 
informative to the study topic. 
Another threat to external validity was not knowing who actually filled out the 
survey. Although this was a confidential survey, there was no way to prove that the CDD 
was the one who answered all or some of the questions. Moreover, there may be external 





compensation, or the short survey time frame that might have impacted their desire to 
participate.  
According to Shadish, Cook, and Campbell (2002), one threat to internal validity 
is ambiguous temporal precedence. What this means is that, based on the study design, 
causality cannot be determined and that a researcher cannot conclude with certainty 
which variable causes another; the researcher is only showing that the variables have an 
association to one another. This often occurs in situations involving ongoing processes 
that interact with one another and, in turn, be affected by one another (Trochim, 2006). 
This phenomenon was evident in the discussion about state genomic funding and the 
level of knowledge and interests in genomics by the CDDs in this study. The fact that 
genomics funding was not significantly associated with CDD knowledge and interest 
means that the higher knowledge and interest is occurring regardless and, at this point in 
time, is not causing an increase in funding for genomics implementation. Finally, there is 
always the possibility that a third variable that was not explored in this study could be the 
causative agent for the results seen (Trochim, 2006).  
Recommendations 
Because state and territorial CDDs will likely be instrumental leaders in the 
success of chronic disease genomics implementation, further research of this group is 
warranted. Although the results of this study showed some significant associations, had 
there been a larger sample size, findings that were not significant at the .05 level could 
have been statistically significant (Rudestam & Newton, 2015). It would be prudent to 





more detailed profile of what they know and what they feel they need to know in order to 
be familiar enough with public health genomics; chronic disease genomics programming; 
identification and contact with collaborators, partners, and stakeholders; and possible 
implications to lead these efforts. Gaining an understanding of what CDDs see as 
potential barriers to implementation or why some CDDs have greater knowledge without 
funding or activities would also be important.  
Another area to examine would be to study current state genomic activities in 
depth to find out exactly what states are doing what, who the champions are, and what, if 
any, partnerships are being formed within the states or among the states. This could be 
instrumental in determining who the next 19–20 states are that might be more successful 
in implementing chronic disease genomics programming based on Rogers’ theory (early 
majority). The states that are ready to move forward could be the focus of educational 
interventions, financial support, and collaborative efforts. This investigation could be 
performed with a more extensive state activity survey or possible phone interview.  
Assessing organizational readiness for chronic disease genomics implementation 
by state health departments could identify other areas that may hinder genomics 
implementation (Stamatakis et al., 2012). State health departments will have a greater 
impact on population health if they are effectively run, have adequate resources, 
competent staff, and utilize evidence-based decision making (Alongi, 2015; Maylahn et 
al., 2013). Innovation adoption doesn’t occur, however, without individual and 
organizational changes based on clear effectiveness and cost effectiveness of the 





benefits of Tier 1 genomic applications will be important. Finally, investigating 
organizational innovativeness and support structure for genomics implementation (Oishi 
et al., 2015) could help identify avenues for adoption in more states.  
St Pierre et al. (2014) explained that chronic disease genomics implementation 
will have a greater chance of success if leadership capacity is developed, incorporated 
into population-based assessment, surveillance, and disease prevention programming, and 
genomic education is provided to public health and healthcare practitioners, policy 
makers, and the public. Of course, all of these endeavors require funding. One of the 
problems in the current climate is that most funding for genomic research is in the 
discovery phase (T1) and very little is provided towards implementation (T4;Glasgow et 
al., 2012; Schully, Benedicto, Gillanders, Wang, & Khoury, 2011). More research must 
be done to show the benefits of chronic disease genomics programming for state and 
territorial populations to encourage funding to that end. 
Implications for Social Change 
It could be argued that inheritance of genetic mutations that predispose an 
individual to an increased susceptibility of certain chronic diseases would eventually 
impact their feelings of health and well-being. The manifestation of these conditions, of 
course, is not only due to these genetic mutations, but also impacted by many other 
social, environmental, cultural, economic, and political circumstances. Public health 
professionals have a responsibility to safeguard the health of people and the communities 
in which they live by working to “assure the conditions in which people can be healthy” 





professionals improve population health through program and policy implementation that 
targets vulnerable communities and other stakeholders while also developing and 
delivering education to assure understanding of potential effects (Godwin & Heymann, 
2015).  
The overarching goal of my research in this study and beyond is to find 
opportunities and barriers to genomic technology implementation in healthcare and 
public health. The results of this study showed some opportunities to increased 
knowledge and interest in genomics by CDDs and putting those in place in more states 
could lead to an increase in chronic disease genomics programming. That would lead to 
greater access to identification of individuals at risk of these conditions and possible 
prevention or reduction of manifestations. Once an individual has been documented, this 
could then have a ripple effect of identification for their family members, communities as 
well as whole populations and have a larger impact on morbidity and mortality from 
these hereditary conditions.  
Conclusion 
The completion of the Human Genome Project in 2003 has allowed public health 
to practice in a more personalized and precise manner and has also been shown to 
improve health outcomes (Auffray et al., 2016).  Evidence exists for population screening 
of affected individuals and their family members for three common chronic diseases with 
a known hereditary component, yet only a small number of states are currently doing any 





influential position to lead chronic disease genomic programming in their states and it is 
important to identify ways to help them reach that goal.  
Rogers’ diffusion of innovations theory demonstrates that adoption of chronic 
disease genomics programming is ready to move into more states. Rogers’ (2003) theory 
also explains that this next group (early majority) is an important link in the diffusion 
process, between the risk-takers and the skeptics, but may take somewhat longer to adopt 
these processes. Determination of what states will be involved in this next phase will be 
critical to overall chronic disease genomic adoption success. The results of this study 
could identify some of those next 19–20 states, particularly those who already have 
CDDs with a greater knowledge and interest in genomics, to address integration of 
particular activities (as I found in this study) or focus funding. 
 In order to fulfill the promise of precision medicine through genomics, more 
research needs to be done to understand what is hindering the translation of this promise 
into reality. Unfortunately, existing knowledge is limited and implementation continues 
to be slow ( Manolio et al., 2013; Roberts, Kennedy, Chambers, & Khoury, 2017). 
Increased integration of evidence-based genomic applications, such as Tier 1 chronic 
disease conditions, to diverse populations will increase the empirical evidence needed to 
show the impact this technology can have on population health. State and territorial 
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Appendix: The Chronic Disease Director’s Survey with Coding 
 
Chronic Disease Director Survey 
Q11 Has your state/territory conducted a genetics needs assessment? 
m   Yes	  (1)	  
m   No	  (2)	  
m   I	  Don't	  Know	  (3)	  
	  
Q29 Did the genetics needs assessment include any action around genomics in chronic disease? 
m   Yes	  (1)	  
m   No	  (2)	  
m   I	  don't	  know	  (3)	  
	  
Q13 Is genetics included in your state action plans for: 
	   Yes	  (1)	   No	  (2)	   Don't	  Know	  (3)	  
Chronic	  Disease	  (1)	   m   	   m   	   m   	  
Cancer	  Control	  (2)	   m   	   m   	   m   	  
Cardiovascular	  Health	  (3)	   m   	   m   	   m   	  
Other	  (e.g.	  asthma,	  
arthritis,	  Alzheimer's);	  
please	  specify	  (4)	  
m   	   m   	   m   	  
 
Q8 Has your state integrated genetics education into programming for any of the following conditions: 
	   Yes	  (1)	   No	  (2)	   Don't	  Know	  (3)	  
Breast	  Cancer	  (1)	   m   	   m   	   m   	  
Colorectal	  Cancer	  (2)	   m   	   m   	   m   	  
Ovarian	  Cancer	  (3)	   m   	   m   	   m   	  
Cardiovascular	  Disease	  (4)	   m   	   m   	   m   	  
Other	  (please	  specify)	  (5)	   m   	   m   	   m   	  
 
Q9 Do you currently include genomics-related questions on the following topics in the BRFSS? 
	   Yes	  (1)	   No	  (2)	   Don't	  Know	  (3)	  
Breast	  and	  Cervical	  Cancer	  
Screening	  (1)	   m   	   m   	   m   	  
Cardiovascular	  Health	  (2)	   m   	   m   	   m   	  
Colorectal	  Cancer	  
Screening	  (3)	   m   	   m   	   m   	  
Health	  Care	  Access	  (4)	   m   	   m   	   m   	  
Genetic	  discrimination	  (5)	   m   	   m   	   m   	  
Privacy	  (6)	   m   	   m   	   m   	  
Direct-­‐to-­‐Consumer	  






Q10 Has your state/territory analyzed state cancer registry or other vital records data to determine the number of 
citizens who might be affected by hereditary cancer syndromes? 
m   Yes	  (1)	  
m   No	  (2)	  
m   Don't	  Know	  (3)	  
 
Q26 If yes, when was the most recent year you analyzed these records and for what diseases/conditions? 
 
Q25 How often do you engage in collaboration or partnership related to genomics with the following groups? 
	   In	  the	  past	  
quarter	  (1)	  
In	  the	  past	  year	  
(2)	  
Rarely	  (3)	   Never	  (4)	   Never	  but	  
Potentially	  in	  the	  
Future	  (5)	  
Academic	  
Institutions	  (1)	   m   	   m   	   m   	   m   	   m   	  
Primary	  care	  
providers	  (2)	   m   	   m   	   m   	   m   	   m   	  
Genetic	  
Counselors	  (3)	   m   	   m   	   m   	   m   	   m   	  
Other	  clinicians	  
(4)	   m   	   m   	   m   	   m   	   m   	  
Advocacy	  Groups	  




m   	   m   	   m   	   m   	   m   	  
Third	  party	  
payers	  (7)	   m   	   m   	   m   	   m   	   m   	  
Local	  and	  county	  
health	  
departments	  (8)	  




m   	   m   	   m   	   m   	   m   	  
 
 
Q15 Does your state/territory have legislation and/or regulations specifically related to genetics, such as: 
	   Yes	  (1)	   No	  (2)	   Don't	  Know	  (3)	  
Non-­‐discrimination	  laws	  
(1)	   m   	   m   	   m   	  
Privacy	  rules	  (2)	   m   	   m   	   m   	  
Informed	  consent	  (3)	   m   	   m   	   m   	  
Funding	  a	  State	  Genetics	  
Coordinator	  position	  (4)	   m   	   m   	   m   	  
Providing	  genetic	  services	  
to	  uninsured	  or	  low-­‐
income	  residents	  (5)	  






Q16 If you needed to refer patients to clinicians for genetic services, or if you wanted to consult someone with 
expertise in genetics, would you know how to contact or locate genetics professionals in your state/territory? 
m   Yes	  (1)	  
m   No	  (2)	  
 
Q22 On a scale of 1-5 (with 1 very poor and 5 very good, how would you rate your knowledge of: 
	   1	  (1)	   2	  (2)	   3	  (3)	   4	  (4)	   5	  (5)	  
Hereditary	  
Breast/Ovarian	  
Cancer	  Syndrome	  (1)	  
m   	   m   	   m   	   m   	   m   	  










Q23 To what extent do you agree or disagree with the following statements? 
	   Strongly	  
Disagree	  (1)	  
Disagree	  (2)	   Neither	  
Agree	  nor	  
Disagree	  (3)	  









influences	  risk	  of	  
chronic	  disease.	  
(1)	  
m   	   m   	   m   	   m   	   m   	   m   	  
As	  a	  whole,	  staff	  
























residents	  of	  our	  
state.	  (4)	  




are	  adequate	  in	  
our	  state.	  (5)	  
m   	   m   	   m   	   m   	   m   	   m   	  


















Q24 In my role as a chronic disease director (CDD), I would be interested in: 
	   Strongly	  
Disagree	  (1)	  
Disagree	  (2)	   Neither	  
Agree	  nor	  
Disagree	  (3)	  
Agree	  (4)	   Strongly	  
Agree	  (5)	  
We	  already	  
do	  this	  (6)	  
Recommending	  the	  
addition	  of	  genomics	  
questions	  to	  the	  BRFSS	  
cancer	  modules	  (1)	  
m   	   m   	   m   	   m   	   m   	   m   	  
Utilizing	  Cancer	  
Registry	  data	  to	  
identify	  high	  risk	  
patients	  with	  the	  goal	  
of	  reducing	  morbidity	  
and	  mortality	  (2)	  
m   	   m   	   m   	   m   	   m   	   m   	  
Incorporating	  genomics	  
into	  our	  comprehensive	  
cancer	  action	  plan.	  (3)	  
m   	   m   	   m   	   m   	   m   	   m   	  
Incorporating	  genomics	  
into	  other	  cancer	  
policies	  and	  initiatives.	  
(4)	  
m   	   m   	   m   	   m   	   m   	   m   	  
Incorporating	  cancer	  
genomics	  into	  our	  
state’s	  Breast	  and	  
Cervical	  Cancer	  Early	  
Detection	  Program.	  (5)	  




screening	  for	  Familial	  
Hypercholesterolemia	  




m   	   m   	   m   	   m   	   m   	   m   	  
Promoting	  or	  
enhancing	  genomics	  
awareness	  among	  the	  
general	  public.	  (7)	  




medical	  providers	  (8)	  
m   	   m   	   m   	   m   	   m   	   m   	  
Finding	  funding	  to	  hire	  
an	  individual	  to	  focus	  
on	  genomics	  and	  
chronic	  disease	  
programming	  (9)	  






 What state or territory do you work with? 
m   Alabama	  (1)	  
m   Alaska	  (2)	  
m   Arizona	  (3)	  
m   Arkansas	  (4)	  
m   California	  (5)	  
m   Colorado	  (6)	  
m   Connecticut	  (7)	  
m   Delaware	  (8)	  
m   Florida	  (9)	  
m   Georgia	  (10)	  
m   Hawaii	  (11)	  
m   Idaho	  (12)	  
m   Illinois	  (13)	  
m   Indiana	  (14)	  
m   Iowa	  (15)	  
m   Kansas	  (16)	  
m   Kentucky	  (17)	  
m   Louisiana	  (18)	  
m   Maine	  (19)	  
m   Maryland	  (20)	  
m   Massachusetts	  (21)	  
m   Michigan	  (22)	  
m   Minnesota	  (23)	  
m   Mississippi	  (24)	  
m   Missouri	  (25)	  
m   Montana	  (26)	  
m   Nebraska	  (27)	  
m   Nevada	  (28)	  
m   New	  Hampshire	  (29)	  
m   New	  Jersey	  (30)	  
m   New	  Mexico	  (31)	  
m   New	  York	  (32)	  
m   North	  Carolina	  (33)	  
m   North	  Dakota	  (34)	  
m   Ohio	  (35)	  
m   Oklahoma	  (36)	  
m   Oregon	  (37)	  
m   Pennsylvania	  (38)	  
m   Rhode	  Island	  (39)	  
m   South	  Carolina	  (40)	  
m   South	  Dakota	  (41)	  
m   Tennessee	  (42)	  
m   Texas	  (43)	  
m   Utah	  (44)	  
m   Vermont	  (45)	  
m   Virginia	  (46)	  





m   West	  Virginia	  (48)	  
m   Wisconsin	  (49)	  
m   Wyoming	  (50)	  
m   Puerto	  Rico	  (51)	  
m   Guam	  (52)	  
m   Northern	  Marianas	  (53)	  
m   United	  States	  Virgin	  Islands	  (54)	  
m   American	  Samoa	  (55)	  
 
Q18 Please indicate your age 
m   21-­‐30	  (1)	  
m   31-­‐40	  (2)	  
m   41-­‐50	  (3)	  
m   51-­‐60	  (4)	  
m   60+	  (5)	  
 
Q20 Please indicate any degrees or board certifications you hold (i.e. MD, MPH, MBA, PhD, BA, etc.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
